Lars Gullestad

  • Professor MD, PhD
  • +47 23070641
 

Publications 2019

Arora S, Ofstad AP, Ulimoen GR, Birkeland KI, Endresen K, Gullestad L, Johansen OE (2019)
Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation
Cardiovasc Diabetol, 18 (1), 26
DOI 10.1186/s12933-019-0832-2, PubMed 30851727

Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) investigators (2019)
S1Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study
Transplantation (in press)
DOI 10.1097/TP.0000000000002702, PubMed 30893292

Nytrøen K, Rolid K, Andreassen AK, Yardley M, Gude E, Dahle DO, Bjørkelund E, Authen AR, Grov I, Wigh JP, Dall CH, Gustafsson F, Karason K, Gullestad L (2019)
Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia: 1-Year Follow-Up of the HITTS Randomized, Controlled Study
Circulation (in press)
DOI 10.1161/CIRCULATIONAHA.118.036747, PubMed 30773030

Peersen K, Otterstad JE, Sverre E, Perk J, Gullestad L, Moum T, Dammen T, Munkhaugen J (2019)
Medical and Psychosocial Factors Associated With Low Physical Activity and Increasing Exercise Level After a Coronary Event
J Cardiopulm Rehabil Prev (in press)
DOI 10.1097/HCR.0000000000000399, PubMed 30720643

Solberg OG, Stavem K, Ragnarsson A, Beitnes JO, Skårdal R, Seljeflot I, Ueland T, Aukrust P, Gullestad L, Aaberge L (2019)
Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study
Catheter Cardiovasc Interv (in press)
DOI 10.1002/ccd.28157, PubMed 30790446

Publications 2018

Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T (2018)
T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF
Clin Res Cardiol, 108 (2), 133-141
DOI 10.1007/s00392-018-1331-2, PubMed 30051179

Andreassen AK, Broch K, Eiskjær H, Karason K, Gude E, Mølbak D, Stueflotten W, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De-novo stUdy with earLy calcineurin inhibitors avoidancE) investigators (2018)
Blood Pressure in De novo Heart Transplant Recipients Treated with Everolimus Compared with a Cyclosporine-Based Regimen: Results from the Randomized SCHEDULE Trial
Transplantation (in press)
DOI 10.1097/TP.0000000000002445, PubMed 30211826

Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L, SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators (2018)
Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients
Circ Heart Fail, 11 (9), e004050
DOI 10.1161/CIRCHEARTFAILURE.117.004050, PubMed 30354362

Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJV, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L et al. (2018)
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
Eur J Heart Fail, 20 (5), 888-895
DOI 10.1002/ejhf.1146, PubMed 29488676

Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL (2018)
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T
J Am Coll Cardiol, 72 (19), 2309-2320
DOI 10.1016/j.jacc.2018.08.2165, PubMed 30384887

Espeland T, Lunde IG, Amundsen BH, Gullestad L, Aakhus S (2018)
Myocardial Fibrosis
Tidsskr. Nor. Laegeforen., 138 (16), 1533-1539

Espeland T, Lunde IG, Amundsen BH, Gullestad L, Aakhus S (2018)
Espeland and co-workers respond
Tidsskr Nor Laegeforen, 138 (19)
DOI 10.4045/tidsskr.18.0865, PubMed 30497251

Espeland T, Lunde IG, H Amundsen B, Gullestad L, Aakhus S (2018)
Myocardial fibrosis
Tidsskr Nor Laegeforen, 138 (16)
DOI 10.4045/tidsskr.17.1027, PubMed 30344312

Heier M, Ofstad AP, Borja MS, Brunborg C, Endresen K, Gullestad L, Birkeland KI, Johansen OE, Oda MN (2018)
High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes
Atherosclerosis, 282, 183-187
DOI 10.1016/j.atherosclerosis.2018.07.005, PubMed 30017177

Hussain AI, Auensen A, Brunborg C, Beitnes JO, Gullestad L, Pettersen KI (2018)
Age-dependent morbidity and mortality outcomes after surgical aortic valve replacement
Interact Cardiovasc Thorac Surg, 27 (5), 650-656
DOI 10.1093/icvts/ivy154, PubMed 29746650

Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K, Holte E, Ryan L, Amundsen BH, Bendz B, Aakhus S, Espevik T, Halvorsen B, Mollnes TE, Wiseth R, Gullestad L, Aukrust P, Damås JK (2018)
Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
Int J Cardiol, 271, 1-7
DOI 10.1016/j.ijcard.2018.04.136, PubMed 29961572

Kvaslerud AB, Hussain AI, Auensen A, Ueland T, Michelsen AE, Pettersen KI, Aukrust P, Mørkrid L, Gullestad L, Broch K (2018)
Prevalence and prognostic implication of iron deficiency and anaemia in patients with severe aortic stenosis
Open Heart, 5 (2), e000901
DOI 10.1136/openhrt-2018-000901, PubMed 30613413

Mayerhofer CCK, Awoyemi AO, Moscavitch SD, Lappegård KT, Hov JR, Aukrust P, Hovland A, Lorenzo A, Halvorsen S, Seljeflot I, Gullestad L, Trøseid M, Broch K (2018)
Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial
ESC Heart Fail, 5 (5), 977-984
DOI 10.1002/ehf2.12332, PubMed 30088346

Munkhaugen J, Hjelmesæth J, Otterstad JE, Helseth R, Sollid ST, Gjertsen E, Gullestad L, Perk J, Moum T, Husebye E, Dammen T (2018)
Managing patients with prediabetes and type 2 diabetes after coronary events: individual tailoring needed - a cross-sectional study
BMC Cardiovasc Disord, 18 (1), 160
DOI 10.1186/s12872-018-0896-z, PubMed 30075751

Munkhaugen J, Otterstad JE, Dammen T, Gjertsen E, Moum T, Husebye E, Gullestad L (2018)
The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event
Eur J Prev Cardiol, 25 (9), 923-931
DOI 10.1177/2047487318768940, PubMed 29635941

Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE (2018)
The follow-up after myocardial infarction- is it good enough?
Tidsskr. Nor. Laegeforen., 138 (5), 434-437

Munkhaugen J, Peersen K, Sverre E, Gjertsen E, Gullestad L, Dammen T, Husebye E, Otterstad JE (2018)
The follow-up after myocardial infarction - is it good enough?
Tidsskr Nor Laegeforen, 138 (5)
DOI 10.4045/tidsskr.17.1050, PubMed 29513442

Norum HM, Michelsen AE, Lekva T, Arora S, Otterdal K, Olsen MB, Kong XY, Gude E, Andreassen AK, Solbu D, Karason K, Dellgren G, Gullestad L, Aukrust P, Ueland T (2018)
Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression
Am J Transplant (in press)
DOI 10.1111/ajt.15141, PubMed 30312541

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
Author's response to: letter to the editor
Heart Fail Rev, 23 (5), 819
DOI 10.1007/s10741-018-9728-6, PubMed 30043131

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Heart Fail Rev, 23 (3), 303-323
DOI 10.1007/s10741-018-9685-0, PubMed 29516230

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
Response to the editor
Heart Fail Rev (in press)
DOI 10.1007/s10741-018-9723-y, PubMed 29968222

Orrem HL, Nilsson PH, Pischke SE, Kleveland O, Yndestad A, Ekholt K, Damås JK, Espevik T, Bendz B, Halvorsen B, Gregersen I, Wiseth R, Andersen GØ, Ueland T, Gullestad L, Aukrust P, Barratt-Due A, Mollnes TE (2018)
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction
Front Immunol, 9, 2035
DOI 10.3389/fimmu.2018.02035, PubMed 30258440

Rolid K, Andreassen AK, Yardley M, Bjørkelund E, Karason K, Wigh JP, Dall CH, Gustafsson F, Gullestad L, Nytrøen K (2018)
Clinical features and determinants of VO2peak in de novo heart transplant recipients
World J Transplant, 8 (5), 188-197
DOI 10.5500/wjt.v8.i5.188, PubMed 30211027

Tegn N, Abdelnoor M, Aaberge L, Hylen Ranhoff A, Endresen K, Gjertsen E, Skårdal R, Gullestad L, Bendz B, After Eighty study investigators (2018)
Health-related quality of life in older patients with acute coronary syndrome randomised to an invasive or conservative strategy. The After Eighty randomised controlled trial
Age Ageing, 47 (1), 42-47
DOI 10.1093/ageing/afx121, PubMed 28985265

Traaen GM, Aakerøy L, Hunt TE, Øverland B, Lyseggen E, Aukrust P, Ueland T, Helle-Valle T, Steinshamn S, Edvardsen T, Khiabani Zaré H, Aakhus S, Akre H, Anfinsen OG, Loennechen JP, Gullestad L (2018)
Treatment of sleep apnea in patients with paroxysmal atrial fibrillation: design and rationale of a randomized controlled trial
Scand Cardiovasc J, 52 (6), 372-377
DOI 10.1080/14017431.2019.1567933, PubMed 30638392

Ueland T, Gullestad L, Kou L, Aukrust P, Anand IS, Broughton MN, McMurray JJ, van Veldhuisen DJ, Warren DJ, Bolstad N (2018)
Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study
ESC Heart Fail, 5 (6), 1052-1059
DOI 10.1002/ehf2.12312, PubMed 30145817

Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Aukrust P, Gullestad L, Halvorsen B, Yndestad A (2018)
Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction
Open Heart, 5 (2), e000765
DOI 10.1136/openhrt-2017-000765, PubMed 30258647

Ueland T, Kleveland O, Michelsen AE, Wiseth R, Damås JK, Holven KB, Aukrust P, Gullestad L, Yndestad A, Halvorsen B (2018)
Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction
Int J Cardiol, 274, 348-350
DOI 10.1016/j.ijcard.2018.06.093, PubMed 29961573

Yardley M, Gullestad L, Nytrøen K (2018)
Importance of physical capacity and the effects of exercise in heart transplant recipients
World J Transplant, 8 (1), 1-12
DOI 10.5500/wjt.v8.i1.1, PubMed 29507857

Publications 2017

Abraityte A, Lunde IG, Askevold ET, Michelsen AE, Christensen G, Aukrust P, Yndestad A, Fiane A, Andreassen A, Aakhus S, Dahl CP, Gullestad L, Broch K, Ueland T (2017)
Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy
Sci Rep, 7 (1), 3490
DOI 10.1038/s41598-017-03625-9, PubMed 28615692

Abraityte A, Vinge LE, Askevold ET, Lekva T, Michelsen AE, Ranheim T, Alfsnes K, Fiane A, Aakhus S, Lunde IG, Dahl CP, Aukrust P, Christensen G, Gullestad L, Yndestad A, Ueland T (2017)
Wnt5a is elevated in heart failure and affects cardiac fibroblast function
J Mol Med (Berl), 95 (7), 767-777
DOI 10.1007/s00109-017-1529-1, PubMed 28357477

Auensen A, Hussain AI, Bendz B, Aaberge L, Falk RS, Walle-Hansen MM, Bye J, Andreassen J, Beitnes JO, Rein KA, Pettersen KI, Gullestad L (2017)
Morbidity outcomes after surgical aortic valve replacement
Open Heart, 4 (1), e000588
DOI 10.1136/openhrt-2017-000588, PubMed 28674629

Broch K, de Marchi SF, Massey R, Hisdal J, Aakhus S, Gullestad L, Urheim S (2017)
Left Ventricular Contraction Pattern in Chronic Aortic Regurgitation and Preserved Ejection Fraction: Simultaneous Stress-Strain Analysis by Three-Dimensional Echocardiography
J Am Soc Echocardiogr, 30 (4), 422-430.e2
DOI 10.1016/j.echo.2016.11.012, PubMed 28065583

Broch K, Leren IS, Saberniak J, Ueland T, Edvardsen T, Gullestad L, Haugaa KH (2017)
Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy
Biomarkers, 22 (3-4), 367-371
DOI 10.1080/1354750X.2016.1278266, PubMed 28067540

Bürker BS, Gude E, Gullestad L, Grov I, Relbo Authen A, Andreassen AK, Havik OE, Dew MA, Fiane AE, Haraldsen IR, Malt UF, Andersson S (2017)
Cognitive function among long-term survivors of heart transplantation
Clin Transplant, 31 (12)
DOI 10.1111/ctr.13143, PubMed 29055147

Bürker BS, Gullestad L, Gude E, Relbo Authen A, Grov I, Hol PK, Andreassen AK, Arora S, Dew MA, Fiane AE, Haraldsen IR, Malt UF, Andersson S (2017)
Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens
Clin Transplant, 31 (4)
DOI 10.1111/ctr.12927, PubMed 28185318

Gude E, Gullestad L, Andreassen AK (2017)
Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
Curr Opin Organ Transplant, 22 (3), 198-206
DOI 10.1097/MOT.0000000000000409, PubMed 28463861

Günther A, Andersen R, Gude E, Jakobsen J, Edvardsen T, Sandvik L, Abildgaard A, Aaberge L, Gullestad L (2017)
The predictive value of coronary artery calcium detected by computed tomography in a prospective study on cardiac allograft vasculopathy in heart transplant patients
Transpl Int, 31 (1), 82-91
DOI 10.1111/tri.13057, PubMed 28865096

Holte E, Kleveland O, Ueland T, Kunszt G, Bratlie M, Broch K, Michelsen AE, Bendz B, Amundsen BH, Aakhus S, Damås JK, Gullestad L, Aukrust P, Wiseth R (2017)
Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction
Heart, 103 (19), 1521-1527
DOI 10.1136/heartjnl-2016-310875, PubMed 28432157

Hussain AI, Auensen A, Brunborg C, Aakhus S, Fiane A, Pettersen KI, Gullestad L (2017)
Determinants and Outcome of Decision Making Among Patients with Severe Aortic Stenosis
J Heart Valve Dis, 26 (4), 413-422
PubMed 29302940

Klaeboe LG, Haland TF, Leren IS, Ter Bekke RMA, Brekke PH, Røsjø H, Omland T, Gullestad L, Aakhus S, Haugaa KH, Edvardsen T (2017)
Prognostic Value of Left Ventricular Deformation Parameters in Patients with Severe Aortic Stenosis: A Pilot Study of the Usefulness of Strain Echocardiography
J Am Soc Echocardiogr, 30 (8), 727-735.e1
DOI 10.1016/j.echo.2017.04.009, PubMed 28599826

Mayerhofer CCK, Ueland T, Broch K, Vincent RP, Cross GF, Dahl CP, Aukrust P, Gullestad L, Hov JR, Trøseid M (2017)
Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure
J Card Fail, 23 (9), 666-671
DOI 10.1016/j.cardfail.2017.06.007, PubMed 28688889

Munkhaugen J, Sverre E, Otterstad JE, Peersen K, Gjertsen E, Perk J, Gullestad L, Moum T, Dammen T, Husebye E (2017)
Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients
Eur J Prev Cardiol, 24 (9), 981-989
DOI 10.1177/2047487317693134, PubMed 28196429

Nelson LM, Andreassen AK, Andersson B, Gude E, Eiskjær H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F (2017)
Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation
Transplantation, 101 (11), 2793-2800
DOI 10.1097/TP.0000000000001706, PubMed 28230646

Norum HM, Broch K, Michelsen AE, Lunde IG, Lekva T, Abraityte A, Dahl CP, Fiane AE, Andreassen AK, Christensen G, Aakhus S, Aukrust P, Gullestad L, Ueland T (2017)
The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy
J Cardiovasc Transl Res, 10 (4), 401-410
DOI 10.1007/s12265-017-9748-y, PubMed 28474304

Nymo SH, Aukrust P, Kjekshus J, McMurray JJ, Cleland JG, Wikstrand J, Muntendam P, Wienhues-Thelen U, Latini R, Askevold ET, Gravning J, Dahl CP, Broch K, Yndestad A, Gullestad L, Ueland T, CORONA Study Group (2017)
Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure
JACC Heart Fail, 5 (4), 256-264
DOI 10.1016/j.jchf.2017.01.008, PubMed 28359413

Olsen MB, Hildrestrand GA, Scheffler K, Vinge LE, Alfsnes K, Palibrk V, Wang J, Neurauter CG, Luna L, Johansen J, Øgaard JDS, Ohm IK, Slupphaug G, Kuśnierczyk A, Fiane AE, Brorson SH, Zhang L, Gullestad L, Louch WE, Iversen PO, Østlie I, Klungland A, Christensen G, Sjaastad I, Sætrom P et al. (2017)
NEIL3-Dependent Regulation of Cardiac Fibroblast Proliferation Prevents Myocardial Rupture
Cell Rep, 18 (1), 82-92
DOI 10.1016/j.celrep.2016.12.009, PubMed 28052262

Peersen K, Munkhaugen J, Gullestad L, Dammen T, Moum T, Otterstad JE (2017)
Reproducibility of an extensive self-report questionnaire used in secondary coronary prevention
Scand J Public Health, 45 (3), 269-276
DOI 10.1177/1403494816688375, PubMed 28181463

Peersen K, Munkhaugen J, Gullestad L, Liodden T, Moum T, Dammen T, Perk J, Otterstad JE (2017)
The role of cardiac rehabilitation in secondary prevention after coronary events
Eur J Prev Cardiol, 24 (13), 1360-1368
DOI 10.1177/2047487317719355, PubMed 28664773

Relbo Authen A, Grov I, Karason K, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Dellgren G, Solbu D, Arora S, Andreassen AK, Gullestad L (2017)
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE)
Clin Transplant, 31 (9)
DOI 10.1111/ctr.13038, PubMed 28640529

Rutkovskiy A, Sagave J, Czibik G, Baysa A, Zihlavnikova Enayati K, Hillestad V, Dahl CP, Fiane A, Gullestad L, Gravning J, Ahmed S, Attramadal H, Valen G, Vaage J (2017)
Connective tissue growth factor and bone morphogenetic protein 2 are induced following myocardial ischemia in mice and humans
Scand J Clin Lab Invest, 77 (5), 321-331
DOI 10.1080/00365513.2017.1318447, PubMed 28460577

Shahini N, Michelsen AE, Nilsson PH, Ekholt K, Gullestad L, Broch K, Dahl CP, Aukrust P, Ueland T, Mollnes TE, Yndestad A, Louwe MC (2017)
The alternative complement pathway is dysregulated in patients with chronic heart failure
Sci Rep, 7, 42532
DOI 10.1038/srep42532, PubMed 28195242

Sverre E, Otterstad JE, Gjertsen E, Gullestad L, Husebye E, Dammen T, Moum T, Munkhaugen J (2017)
Medical and sociodemographic factors predict persistent smoking after coronary events
BMC Cardiovasc Disord, 17 (1), 241
DOI 10.1186/s12872-017-0676-1, PubMed 28877684

Sverre E, Peersen K, Husebye E, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Dammen T, Munkhaugen J (2017)
Unfavourable risk factor control after coronary events in routine clinical practice
BMC Cardiovasc Disord, 17 (1), 40
DOI 10.1186/s12872-016-0387-z, PubMed 28109259

Sverre E, Peersen K, Otterstad JE, Gullestad L, Perk J, Gjertsen E, Moum T, Husebye E, Dammen T, Munkhaugen J (2017)
Optimal blood pressure control after coronary events: the challenge remains
J Am Soc Hypertens, 11 (12), 823-830
DOI 10.1016/j.jash.2017.10.007, PubMed 29128603

Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV (2017)
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study
Eur J Heart Fail, 20 (2), 268-277
DOI 10.1002/ejhf.988, PubMed 28960777

Yardley M, Ueland T, Aukrust P, Michelsen A, Bjørkelund E, Gullestad L, Nytrøen K (2017)
Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients
Open Heart, 4 (2), e000635
DOI 10.1136/openhrt-2017-000635, PubMed 29225901

Publications 2016

Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE investigators (2016)
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study
Am J Transplant, 16 (4), 1238-47
DOI 10.1111/ajt.13588, PubMed 26820618

Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P, Ueland T (2016)
Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)
Biomarkers, 22 (3-4), 261-267
DOI 10.1080/1354750X.2016.1204003, PubMed 27325138

Broch K, Urheim S, Massey R, Stueflotten W, Fosså K, Hopp E, Aakhus S, Gullestad L (2016)
Exercise capacity and peak oxygen consumption in asymptomatic patients with chronic aortic regurgitation
Int J Cardiol, 223, 688-692
DOI 10.1016/j.ijcard.2016.08.237, PubMed 27568990

Dhondup Y, Ueland T, Dahl CP, Askevold ET, Sandanger Ø, Fiane A, Ohm IK, Sjaastad I, Finsen AV, Wæhre A, Gullestad L, Aukrust P, Yndestad A, Vinge LE (2016)
Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure
J Card Fail, 22 (10), 823-8
DOI 10.1016/j.cardfail.2016.06.013, PubMed 27349571

Gullestad L, Eiskjaer H, Gustafsson F, Riise GC, Karason K, Dellgren G, Rådegran G, Hansson L, Gude E, Bjørtuft Ø, Jansson K, Schultz HH, Solbu D, Iversen M (2016)
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial
Transpl Int, 29 (7), 819-29
DOI 10.1111/tri.12783, PubMed 27067532

Hussain AI, Garratt AM, Brunborg C, Aakhus S, Gullestad L, Pettersen KI (2016)
Eliciting Patient Risk Willingness in Clinical Consultations as a Means of Improving Decision-Making of Aortic Valve Replacement
J Am Heart Assoc, 5 (3), e002828
DOI 10.1161/JAHA.115.002828, PubMed 26994130

Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T, Aakhus S, Damås JK, Aukrust P, Wiseth R, Gullestad L (2016)
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
Eur Heart J, 37 (30), 2406-13
DOI 10.1093/eurheartj/ehw171, PubMed 27161611

Mirza K, Gustafsson F, Gullestad L, Arora S, Andersen C (2016)
Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3+ regulatory T cells in heart transplantation
Transpl Immunol, 38, 75-7
DOI 10.1016/j.trim.2016.05.004, PubMed 27260644

Munkhaugen J, Sverre E, Peersen K, Egge Ø, Gjertsen Eikeseth C, Gjertsen E, Gullestad L, Erik Otterstad J, Husebye E, Dammen T (2016)
Patient characteristics and risk factors of participants and non-participants in the NOR-COR study
Scand Cardiovasc J, 50 (5-6), 317-322
DOI 10.1080/14017431.2016.1202445, PubMed 27323914

Solberg OG, Stavem K, Ragnarsson A, Ioanes D, Arora S, Endresen K, Benth JŠ, Gullestad L, Gude E, Andreassen AK, Aaberge L (2016)
Index of microvascular resistance after early conversion from calcineurin inhibitor to everolimus in heart transplantation: A sub-study to a 1-year randomized trial
J Heart Lung Transplant, 35 (8), 1010-7
DOI 10.1016/j.healun.2016.03.002, PubMed 27113960

Soubrier M, Pei J, Durand F, Gullestad L, John A (2016)
Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Rheumatol Ther, 4 (1), 133-149
DOI 10.1007/s40744-016-0049-8, PubMed 27900570

Tegn N, Abdelnoor M, Aaberge L, Endresen K, Gullestad L, Bendz B (2016)
[Not Available]
Tidsskr Nor Laegeforen, 136 (16), 1324-5
DOI 10.4045/tidsskr.16.0685, PubMed 27637033

Tegn N, Abdelnoor M, Aaberge L, Endresen K, Smith P, Aakhus S, Gjertsen E, Dahl-Hofseth O, Ranhoff AH, Gullestad L, Bendz B, After Eighty study investigators (2016)
Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial
Lancet, 387 (10023), 1057-1065
DOI 10.1016/S0140-6736(15)01166-6, PubMed 26794722

Yardley M, Gullestad L, Bendz B, Bjørkelund E, Rolid K, Arora S, Nytrøen K (2016)
Long-term effects of high-intensity interval training in heart transplant recipients: A 5-year follow-up study of a randomized controlled trial
Clin Transplant, 31 (1)
DOI 10.1111/ctr.12868, PubMed 27865004

Publications 2015

Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Sigurdardottir V, Dellgren G, Erikstad I, Solberg OG, Ueland T, Aukrust P, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators (2015)
The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial
Am J Transplant, 15 (7), 1967-75
DOI 10.1111/ajt.13214, PubMed 25783974

Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, Cleland JG, McMurray JJ, Aukrust P, Ueland T (2015)
Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
PLoS One, 10 (8), e0133970
DOI 10.1371/journal.pone.0133970, PubMed 26288364

Baysa A, Sagave J, Carpi A, Zaglia T, Campesan M, Dahl CP, Bilbija D, Troitskaya M, Gullestad L, Giorgio M, Mongillo M, Di Lisa F, Vaage JI, Valen G (2015)
The p66ShcA adaptor protein regulates healing after myocardial infarction
Basic Res Cardiol, 110 (2), 13
DOI 10.1007/s00395-015-0470-0, PubMed 25680868

Broch K, Andreassen AK, Hopp E, Leren TP, Scott H, Müller F, Aakhus S, Gullestad L (2015)
Results of comprehensive diagnostic work-up in 'idiopathic' dilated cardiomyopathy
Open Heart, 2 (1), e000271
DOI 10.1136/openhrt-2015-000271, PubMed 26468400

Broch K, Murbræch K, Andreassen AK, Hopp E, Aakhus S, Gullestad L (2015)
Contemporary Outcome in Patients With Idiopathic Dilated Cardiomyopathy
Am J Cardiol, 116 (6), 952-9
DOI 10.1016/j.amjcard.2015.06.022, PubMed 26233575

Broch K, Urheim S, Lønnebakken MT, Stueflotten W, Massey R, Fosså K, Hopp E, Aakhus S, Gullestad L (2015)
Controlled release metoprolol for aortic regurgitation: a randomised clinical trial
Heart, 102 (3), 191-7
DOI 10.1136/heartjnl-2015-308416, PubMed 26661319

Cowie MR, Woehrle H, Oldenburg O, Damy T, van der Meer P, Erdman E, Metra M, Zannad F, Trochu JN, Gullestad L, Fu M, Böhm M, Auricchio A, Levy P (2015)
Sleep-disordered Breathing in Heart Failure - Current State of the Art
Card Fail Rev, 1 (1), 16-24
DOI 10.15420/cfr.2015.01.01.16, PubMed 28785426

De Blois J, Fagerland MW, Grundtvig M, Semb AG, Gullestad L, Westheim A, Hole T, Atar D, Agewall S (2015)
ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry
Eur Heart J Cardiovasc Pharmacother, 1 (1), 31-6
DOI 10.1093/ehjcvp/pvu010, PubMed 27533962

Dhondup Y, Sjaastad I, Scott H, Sandanger Ø, Zhang L, Haugstad SB, Aronsen JM, Ranheim T, Holmen SD, Alfsnes K, Ahmed MS, Attramadal H, Gullestad L, Aukrust P, Christensen G, Yndestad A, Vinge LE (2015)
Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice
PLoS One, 10 (10), e0139715
DOI 10.1371/journal.pone.0139715, PubMed 26461521

Estensen ME, Grindheim G, Remme EW, Godang K, Henriksen T, Aukrust P, Aakhus S, Gullestad L, Ueland T (2015)
Elevated inflammatory markers in preeclamptic pregnancies, but no relation to systemic arterial stiffness
Pregnancy Hypertens, 5 (4), 325-9
DOI 10.1016/j.preghy.2015.09.003, PubMed 26597749

Fosshaug LE, Dahl CP, Risnes I, Bohov P, Berge RK, Nymo S, Geiran O, Yndestad A, Gullestad L, Aukrust P, Vinge LE, Øie E (2015)
Altered Levels of Fatty Acids and Inflammatory and Metabolic Mediators in Epicardial Adipose Tissue in Patients With Systolic Heart Failure
J Card Fail, 21 (11), 916-23
DOI 10.1016/j.cardfail.2015.07.014, PubMed 26231517

Geir Solberg O, Aaberge L, Ragnarsson A, Aas M, Endresen K, Šaltytė Benth J, Gullestad L, Stavem K (2015)
Comparison of simplified and comprehensive methods for assessing the index of microvascular resistance in heart transplant recipients
Catheter Cardiovasc Interv, 87 (2), 283-90
DOI 10.1002/ccd.26283, PubMed 26525162

Hussain AI, Garratt AM, Beitnes JO, Gullestad L, Pettersen KI (2015)
Validity of standard gamble utilities in patients referred for aortic valve replacement
Qual Life Res, 25 (7), 1703-12
DOI 10.1007/s11136-015-1186-1, PubMed 26603737

Munkhaugen J, Sverre E, Peersen K, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Perk J, Husebye E, Dammen T (2015)
The role of medical and psychosocial factors for unfavourable coronary risk factor control
Scand Cardiovasc J, 50 (1), 1-8
DOI 10.3109/14017431.2015.1111408, PubMed 26488672

Norum HM, Gullestad L, Abraityte A, Broch K, Aakhus S, Aukrust P, Ueland T (2015)
Increased Serum Levels of the Notch Ligand DLL1 are Associated with Diastolic Dysfunction, Reduced Exercise Capacity, and Adverse Outcome in Chronic Heart Failure
J Card Fail, 22 (3), 218-23
DOI 10.1016/j.cardfail.2015.07.012, PubMed 26211721

Nymo SH, Ueland T, Askevold E, Dahl CP, Gullestad L, Aukrust P, Yndestad A (2015)
Circulating nucleosomes in chronic heart failure
Int J Cardiol, 203, 742-3
DOI 10.1016/j.ijcard.2015.10.219, PubMed 26595779

Nytrøen K, Yardley M, Rolid K, Bjørkelund E, Karason K, Wigh JP, Dall CH, Arora S, Aakhus S, Lunde K, Solberg OG, Gustafsson F, Prescott EI, Gullestad L (2015)
Design and rationale of the HITTS randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia
Am Heart J, 172, 96-105
DOI 10.1016/j.ahj.2015.10.011, PubMed 26856221

Ofstad AP, Urheim S, Dalen H, Orvik E, Birkeland KI, Gullestad L, W Fagerland M, Johansen OE, Aakhus S (2015)
Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls
J Diabetes, 7 (6), 779-90
DOI 10.1111/1753-0407.12239, PubMed 25350248

Røysland R, Røsjø H, Høiseth AD, Gullestad L, Badr P, Kravdal G, Omland T (2015)
Osteoprotegerin concentrations in patients with suspected reversible myocardial ischemia: observations from the Akershus Cardiac Examination (ACE) 1 Study
Cytokine, 73 (1), 122-7
DOI 10.1016/j.cyto.2015.01.020, PubMed 25748834

Schurgers LJ, Burgmaier M, Ueland T, Schutters K, Aakhus S, Hofstra L, Gullestad L, Aukrust P, Hellmich M, Narula J, Reutelingsperger CP (2015)
Circulating annexin A5 predicts mortality in patients with heart failure
J Intern Med, 279 (1), 89-97
DOI 10.1111/joim.12396, PubMed 26223343

Ulimoen GR, Ofstad AP, Endresen K, Gullestad L, Johansen OE, Borthne A (2015)
Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes--a cross-sectional study
BMC Cardiovasc Disord, 15, 147
DOI 10.1186/s12872-015-0143-9, PubMed 26573616

Yardley M, Havik OE, Grov I, Relbo A, Gullestad L, Nytrøen K (2015)
Peak oxygen uptake and self-reported physical health are strong predictors of long-term survival after heart transplantation
Clin Transplant, 30 (2), 161-9
DOI 10.1111/ctr.12672, PubMed 26589579

Publications 2014

Abraityte A, Gullestad L, Askevold ET, Nymo S, Dahl CP, Aakhus S, Aukrust P, Ueland T (2014)
The Notch ligand Delta-like 1 is elevated and associated with mortality in patients with symptomatic aortic stenosis
Int J Cardiol, 180, 18-20
DOI 10.1016/j.ijcard.2014.11.111, PubMed 25438200

Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Sigurdardottir V, Arora S, Dellgren G, Gullestad L, SCHEDULE Investigators (2014)
Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial
Am J Transplant, 14 (8), 1828-38
DOI 10.1111/ajt.12809, PubMed 25041227

Apelland T, Gude E, Strøm EH, Gullestad L, Eiklid KL, Månsson JE, Reinholt FP, Houge G, Dahl CP, Almaas VM, Heiberg A (2014)
Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease
Heart, 100 (22), 1793-8
DOI 10.1136/heartjnl-2014-305616, PubMed 25031264

Arora S, Gullestad L (2014)
The challenge of allograft vasculopathy in cardiac transplantation
Curr Opin Organ Transplant, 19 (5), 508-14
DOI 10.1097/MOT.0000000000000112, PubMed 25144667

Askevold ET, Aukrust P, Nymo SH, Lunde IG, Kaasbøll OJ, Aakhus S, Florholmen G, Ohm IK, Strand ME, Attramadal H, Fiane A, Dahl CP, Finsen AV, Vinge LE, Christensen G, Yndestad A, Gullestad L, Latini R, Masson S, Tavazzi L, GISSI-HF Investigators, Ueland T (2014)
The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure
J Intern Med, 275 (6), 621-30
DOI 10.1111/joim.12175, PubMed 24330105

Askevold ET, Gullestad L, Dahl CP, Yndestad A, Ueland T, Aukrust P (2014)
Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure
Curr Heart Fail Rep, 11 (2), 146-55
DOI 10.1007/s11897-014-0185-9, PubMed 24477903

Bilbija D, Elmabsout AA, Sagave J, Haugen F, Bastani N, Dahl CP, Gullestad L, Sirsjö A, Blomhoff R, Valen G (2014)
Expression of retinoic acid target genes in coronary artery disease
Int J Mol Med, 33 (3), 677-86
DOI 10.3892/ijmm.2014.1623, PubMed 24424466

Bot I, Daissormont IT, Zernecke A, van Puijvelde GH, Kramp B, de Jager SC, Sluimer JC, Manca M, Hérias V, Westra MM, Bot M, van Santbrink PJ, van Berkel TJ, Su L, Skjelland M, Gullestad L, Kuiper J, Halvorsen B, Aukrust P, Koenen RR, Weber C, Biessen EA (2014)
CXCR4 blockade induces atherosclerosis by affecting neutrophil function
J Mol Cell Cardiol, 74, 44-52
DOI 10.1016/j.yjmcc.2014.04.021, PubMed 24816217

Broch K, Al-Ani A, Gude E, Gullestad L, Aakhus S (2014)
Echocardiographic evaluation of left ventricular filling pressure in heart transplant recipients
Scand Cardiovasc J, 48 (6), 349-56
DOI 10.3109/14017431.2014.981579, PubMed 25414078

Broch K, Andreassen AK, Ueland T, Michelsen AE, Stueflotten W, Aukrust P, Aakhus S, Gullestad L (2014)
Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure
Int J Cardiol, 179, 378-84
DOI 10.1016/j.ijcard.2014.11.003, PubMed 25464491

Broch K, Askevold ET, Gjertsen E, Ueland T, Yndestad A, Godang K, Stueflotten W, Andreassen J, Svendsmark R, Smith HJ, Aakhus S, Aukrust P, Gullestad L (2014)
The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial
PLoS One, 9 (2), e89732
DOI 10.1371/journal.pone.0089732, PubMed 24586994

Cornu C, Dufays C, Gaillard S, Gueyffier F, Redonnet M, Sebbag L, Roussoulières A, Gleissner CA, Groetzner J, Lehmkuhl HB, Potena L, Gullestad L, Cantarovich M, Boissonnat P (2014)
Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis
Br J Clin Pharmacol, 78 (1), 24-32
DOI 10.1111/bcp.12289, PubMed 24251918

Finsen AV, Ueland T, Sjaastad I, Ranheim T, Ahmed MS, Dahl CP, Askevold ET, Aakhus S, Husberg C, Fiane AE, Lipp M, Gullestad L, Christensen G, Aukrust P, Yndestad A (2014)
The homeostatic chemokine CCL21 predicts mortality in aortic stenosis patients and modulates left ventricular remodeling
PLoS One, 9 (11), e112172
DOI 10.1371/journal.pone.0112172, PubMed 25398010

Gustafsson F, Gude E, Sigurdardottir V, Aukrust P, Solbu D, Goetze JP, Gullestad L (2014)
Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels
Biomark Med, 8 (2), 239-45
DOI 10.2217/bmm.13.95, PubMed 24521021

Halvorsen B, Smedbakken LM, Michelsen AE, Skjelland M, Bjerkeli V, Sagen EL, Taskén K, Bendz B, Gullestad L, Holm S, Biessen EA, Aukrust P (2014)
Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13
Atherosclerosis, 234 (2), 352-9
DOI 10.1016/j.atherosclerosis.2014.03.021, PubMed 24732574

Hasselberg NE, Haugaa KH, Sarvari SI, Gullestad L, Andreassen AK, Smiseth OA, Edvardsen T (2014)
Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction
Eur Heart J Cardiovasc Imaging, 16 (2), 217-24
DOI 10.1093/ehjci/jeu277, PubMed 25552469

Holm T, Færestrand S, Larsen AI, Jønland KB, Gullestad L, Dickstein K, Köpp U, Sirnes PA, Tande P, Steen T, Kongsgård E (2014)
[Cardiac resynchronization therapy in heart failure--Norwegian guidelines]
Tidsskr Nor Laegeforen, 134 (10), E1-17
DOI 10.4045/tidsskr.13.0628, PubMed 24865746

Ofstad AP, Johansen OE, Gullestad L, Birkeland KI, Orvik E, Fagerland MW, Urheim S, Aakhus S (2014)
Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study
Am Heart J, 168 (3), 280-288.e2
DOI 10.1016/j.ahj.2014.03.026, PubMed 25173538

Perez-Moreno AC, Jhund PS, Macdonald MR, Petrie MC, Cleland JG, Böhm M, van Veldhuisen DJ, Gullestad L, Wikstrand J, Kjekshus J, Lewsey JD, McMurray JJ (2014)
Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
JACC Heart Fail, 2 (2), 187-97
DOI 10.1016/j.jchf.2014.01.001, PubMed 24720928

Perez AC, Jhund PS, Stott DJ, Gullestad L, Cleland JG, van Veldhuisen DJ, Wikstrand J, Kjekshus J, McMurray JJ (2014)
Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure)
JACC Heart Fail, 2 (1), 35-40
DOI 10.1016/j.jchf.2013.07.008, PubMed 24622117

Rogers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ (2014)
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)
JACC Heart Fail, 2 (3), 289-97
DOI 10.1016/j.jchf.2013.12.007, PubMed 24952697

Solberg OG, Ragnarsson A, Kvarsnes A, Endresen K, Kongsgard E, Aakhus S, Gullestad L, Stavem K, Aaberge L (2014)
Reference interval for the index of coronary microvascular resistance
EuroIntervention, 9 (9), 69-75

Solberg OG, Ragnarsson A, Kvarsnes A, Endresen K, Kongsgård E, Aakhus S, Gullestad L, Stavem K, Aaberge L (2014)
Reference interval for the index of coronary microvascular resistance
EuroIntervention, 9 (9), 1069-75
DOI 10.4244/EIJV9I9A181, PubMed 24457279

Trøseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, Aakhus S, Gude E, Bjørndal B, Halvorsen B, Karlsen TH, Aukrust P, Gullestad L, Berge RK, Yndestad A (2014)
Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure
J Intern Med, 277 (6), 717-26
DOI 10.1111/joim.12328, PubMed 25382824

Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Block D, Zaugg C, Gullestad L (2014)
Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial
J Card Fail, 21 (2), 153-9
DOI 10.1016/j.cardfail.2014.10.016, PubMed 25451704

Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Wienhues-Thelen UH, Block D, Zaugg C, Gullestad L (2014)
Predictive value of endostatin in chronic heart failure patients with poor kidney function
Cardiology, 130 (1), 17-22
DOI 10.1159/000368220, PubMed 25428583

Ueland T, Gullestad L, Nymo SH, Yndestad A, Aukrust P, Askevold ET (2014)
Inflammatory cytokines as biomarkers in heart failure
Clin Chim Acta, 443, 71-7
DOI 10.1016/j.cca.2014.09.001, PubMed 25199849

Wu X, Sagave J, Rutkovskiy A, Haugen F, Baysa A, Nygård S, Czibik G, Dahl CP, Gullestad L, Vaage J, Valen G (2014)
Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart
Life Sci, 97 (2), 145-54
DOI 10.1016/j.lfs.2013.12.030, PubMed 24398041

Publications 2013

Dahl CP, Aukrust P, Nymo SH, Kjekshus J, Cleland JG, McMurray JJ, Wikstrand J, Gullestad L, Ueland T (2013)
Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure
Int J Cardiol, 168 (4), 4427-9
DOI 10.1016/j.ijcard.2013.05.008, PubMed 23714594

Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, Velazquez EJ, Racine N, Gullestad L, Filgueira JL, Lee KL, STICH Investigators (2013)
Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease
Circ Heart Fail, 6 (3), 443-50
DOI 10.1161/CIRCHEARTFAILURE.112.000130, PubMed 23515275

Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J, CORONA Study Group (2013)
Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial
Circ Heart Fail, 7 (1), 96-103
DOI 10.1161/CIRCHEARTFAILURE.113.000450, PubMed 24284025

Gregersen I, Skjelland M, Holm S, Holven KB, Krogh-Sørensen K, Russell D, Askevold ET, Dahl CP, Ørn S, Gullestad L, Mollnes TE, Ueland T, Aukrust P, Halvorsen B (2013)
Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis
PLoS One, 8 (8), e72769
DOI 10.1371/journal.pone.0072769, PubMed 24023645

Karlson BW, Dellborg M, Gullestad L, Aberg J, Sugg J, Herlitz J (2013)
A pharmacokinetic and pharmacodynamic comparison of immediate-release metoprolol and extended-release metoprolol CR/XL in patients with suspected acute myocardial infarction: a randomized, open-label study
Cardiology, 127 (2), 73-82
DOI 10.1159/000355003, PubMed 24247812

Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L, Heart Failure Association of the European Society of Cardiology (HFA) (2013)
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)
Eur J Heart Fail, 15 (7), 808-17
DOI 10.1093/eurjhf/hft050, PubMed 23537547

Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, Yndestad A, Gullestad L, Aukrust P (2013)
Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA
Eur J Heart Fail, 16 (1), 68-75
DOI 10.1093/eurjhf/hft125, PubMed 23918775

Nytrøen K, Gullestad L (2013)
[Exercise after heart transplantation--old principles needs reevaluation]
Tidsskr Nor Laegeforen, 133 (19), 2030-1
DOI 10.4045/tidsskr.13.0903, PubMed 24129530

Nytrøen K, Gullestad L (2013)
Exercise after heart transplantation: An overview
World J Transplant, 3 (4), 78-90
DOI 10.5500/wjt.v3.i4.78, PubMed 24392312

Nytrøen K, Gullestad L (2013)
Effect of exercise in heart transplant recipients
Am J Transplant, 13 (2), 527
DOI 10.1111/ajt.12046, PubMed 23356900

Nytrøen K, Rustad LA, Erikstad I, Aukrust P, Ueland T, Lekva T, Gude E, Wilhelmsen N, Hervold A, Aakhus S, Gullestad L, Arora S (2013)
Effect of high-intensity interval training on progression of cardiac allograft vasculopathy
J Heart Lung Transplant, 32 (11), 1073-80
DOI 10.1016/j.healun.2013.06.023, PubMed 23906899

Ofstad AP, Gullestad L, Orvik E, Aakhus S, Endresen K, Ueland T, Aukrust P, Fagerland MW, Birkeland KI, Johansen OE (2013)
Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study
Cardiovasc Diabetol, 12, 126
DOI 10.1186/1475-2840-12-126, PubMed 23987834

Prohászka Z, Munthe-Fog L, Ueland T, Gombos T, Yndestad A, Förhécz Z, Skjoedt MO, Pozsonyi Z, Gustavsen A, Jánoskuti L, Karádi I, Gullestad L, Dahl CP, Askevold ET, Füst G, Aukrust P, Mollnes TE, Garred P (2013)
Association of ficolin-3 with severity and outcome of chronic heart failure
PLoS One, 8 (4), e60976
DOI 10.1371/journal.pone.0060976, PubMed 23596511

Robertsen I, Falck P, Andreassen AK, Næss NK, Lunder N, Christensen H, Gullestad L, Asberg A (2013)
Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients
Transplant Res, 2 (1), 5
DOI 10.1186/2047-1440-2-5, PubMed 23566530

Rustad LA, Nytrøen K, Andreassen A, Geiran O, Endresen K, Gullestad L, Aakhus S, Amundsen BH (2013)
Heart transplant systolic and diastolic function is impaired by prolonged pretransplant graft ischaemic time and high donor age: an echocardiographic study
Eur J Cardiothorac Surg, 44 (2), e97-104
DOI 10.1093/ejcts/ezt233, PubMed 23657552

Strand ME, Herum KM, Rana ZA, Skrbic B, Askevold ET, Dahl CP, Vistnes M, Hasic A, Kvaløy H, Sjaastad I, Carlson CR, Tønnessen T, Gullestad L, Christensen G, Lunde IG (2013)
Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart
FEBS J, 280 (10), 2228-47
DOI 10.1111/febs.12161, PubMed 23374111

Ueland T, Nymo SH, Latini R, McMurray JJ, Kjekshus J, Yndestad A, Fucili A, Grosu A, Masson S, Maggioni AP, Gullestad L, Aukrust P, Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial, Investigators of the GISSI-Heart Failure (GISSI-HF) trial (2013)
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials
Eur J Heart Fail, 15 (7), 747-55
DOI 10.1093/eurjhf/hft031, PubMed 23487539

van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA (2013)
Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH
Circ Heart Fail, 6 (2), 219-26
DOI 10.1161/CIRCHEARTFAILURE.112.000129, PubMed 23395934

Publications 2012

Arora S, Erikstad I, Ueland T, Sigurdardottir V, Ekmehag B, Jansson K, Eiskjaer H, Bøtker HE, Mortensen SA, Saunamaki K, Gude E, Ragnarsson A, Solbu D, Aukrust P, Gullestad L (2012)
Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus--results of a multicenter trial
Am J Transplant, 12 (10), 2700-9
DOI 10.1111/j.1600-6143.2012.04234.x, PubMed 22958738

Arora S, Gude E, Sigurdardottir V, Mortensen SA, Eiskjær H, Riise G, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Aukrust P, Solbu D, Iversen M, Gullestad L (2012)
Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate
J Heart Lung Transplant, 31 (3), 259-65
DOI 10.1016/j.healun.2011.12.010, PubMed 22333403

Arora S, Aarones M, Aakhus S, Skaardal R, Aass H, Aukrust P, Kongsgaard E, Gullestad L (2012)
Peak oxygen uptake during cardiopulmonary exercise testing determines response to cardiac resynchronization therapy
J Cardiol, 60 (3), 228-35
DOI 10.1016/j.jjcc.2012.03.004, PubMed 22542140

Askevold ET, Gullestad L, Aakhus S, Ranheim T, Tønnessen T, Solberg OG, Aukrust P, Ueland T (2012)
Secreted Wnt modulators in symptomatic aortic stenosis
J Am Heart Assoc, 1 (6), e002261
DOI 10.1161/JAHA.112.002261, PubMed 23316316

Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, Yndestad A, Cleland JG, McMurray JJ, Aukrust P, Gullestad L (2012)
Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
Circ Heart Fail, 6 (1), 91-8
DOI 10.1161/CIRCHEARTFAILURE.112.972653, PubMed 23230311

Broch K, Eek C, Wergeland R, Ueland T, Skårdal R, Aukrust P, Skulstad H, Gullestad L (2012)
NT-proBNP predicts myocardial recovery after non-ST-elevation acute coronary syndrome
Scand Cardiovasc J, 46 (2), 65-71
DOI 10.3109/14017431.2011.652981, PubMed 22191851

Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Cleland JG, Aukrust P, Gullestad L (2012)
Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology
Eur J Heart Fail, 14 (3), 268-77
DOI 10.1093/eurjhf/hfs006, PubMed 22302661

Broch K, Ueland T, Yndestad A, Aukrust P, Gullestad L (2012)
Heart failure biomarkers: focus on interleukin-1 receptor-like 1-based blood tests
Drugs Today (Barc), 48 (7), 479-91
DOI 10.1358/dot.2012.48.7.1811719, PubMed 22844659

Erikssen G, Liestøl K, Gullestad L, Haugaa KH, Bendz B, Amlie JP (2012)
The terminal part of the QT interval (T peak to T end): a predictor of mortality after acute myocardial infarction
Ann Noninvasive Electrocardiol, 17 (2), 85-94
DOI 10.1111/j.1542-474X.2012.00493.x, PubMed 22537325

Gullestad L, Orn S, Dickstein K, Eek C, Edvardsen T, Aakhus S, Askevold ET, Michelsen A, Bendz B, Skårdal R, Smith HJ, Yndestad A, Ueland T, Aukrust P (2012)
Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction
Int J Cardiol, 168 (1), 212-8
DOI 10.1016/j.ijcard.2012.09.092, PubMed 23046599

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Böhm M, van Veldhuisen DJ, Komajda M, Cleland JG, Wikstrand J, McMurray JJ, Aukrust P, CORONA Study Group (2012)
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
Eur Heart J, 33 (18), 2290-6
DOI 10.1093/eurheartj/ehs077, PubMed 22513778

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P (2012)
The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
Am Heart J, 164 (6), 878-83
DOI 10.1016/j.ahj.2012.08.021, PubMed 23194488

Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012)
Inflammatory cytokines in heart failure: mediators and markers
Cardiology, 122 (1), 23-35
DOI 10.1159/000338166, PubMed 22699305

Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vårdal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L, Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials (2012)
Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials
Eur J Heart Fail, 14 (9), 992-9
DOI 10.1093/eurjhf/hfs092, PubMed 22740508

Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L, Aukrust P, Yndestad A (2012)
The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*
J Intern Med, 271 (5), 436-43
DOI 10.1111/j.1365-2796.2011.02503.x, PubMed 22211640

Nytrøen K, Rustad LA, Aukrust P, Ueland T, Hallén J, Holm I, Rolid K, Lekva T, Fiane AE, Amlie JP, Aakhus S, Gullestad L (2012)
High-intensity interval training improves peak oxygen uptake and muscular exercise capacity in heart transplant recipients
Am J Transplant, 12 (11), 3134-42
DOI 10.1111/j.1600-6143.2012.04221.x, PubMed 22900793

Nytrøen K, Rustad LA, Gude E, Hallén J, Fiane AE, Rolid K, Holm I, Aakhus S, Gullestad L (2012)
Muscular exercise capacity and body fat predict VO(2peak) in heart transplant recipients
Eur J Prev Cardiol, 21 (1), 21-9
DOI 10.1177/2047487312450540, PubMed 22659939

Rustad LA, Nytrøen K, Amundsen BH, Gullestad L, Aakhus S (2012)
One year of high-intensity interval training improves exercise capacity, but not left ventricular function in stable heart transplant recipients: a randomised controlled trial
Eur J Prev Cardiol, 21 (2), 181-91
DOI 10.1177/2047487312469477, PubMed 23185084

Rutkovskiy A, Stensløkken KO, Mariero LH, Skrbic B, Amiry-Moghaddam M, Hillestad V, Valen G, Perreault MC, Ottersen OP, Gullestad L, Dahl CP, Vaage J (2012)
Aquaporin-4 in the heart: expression, regulation and functional role in ischemia
Basic Res Cardiol, 107 (5), 280
DOI 10.1007/s00395-012-0280-6, PubMed 22777185

Sarvari SI, Gjesdal O, Gude E, Arora S, Andreassen AK, Gullestad L, Geiran O, Edvardsen T (2012)
Early postoperative left ventricular function by echocardiographic strain is a predictor of 1-year mortality in heart transplant recipients
J Am Soc Echocardiogr, 25 (9), 1007-14
DOI 10.1016/j.echo.2012.05.010, PubMed 22727199

Sikkeland LI, Dahl CP, Ueland T, Andreassen AK, Gude E, Edvardsen T, Holm T, Yndestad A, Gullestad L, Kongerud J, Aukrust P, Øie E (2012)
Increased levels of inflammatory cytokines and endothelin-1 in alveolar macrophages from patients with chronic heart failure
PLoS One, 7 (5), e36815
DOI 10.1371/journal.pone.0036815, PubMed 22615818

Smedbakken LM, Halvorsen B, Daissormont I, Ranheim T, Michelsen AE, Skjelland M, Sagen EL, Folkersen L, Krohg-Sørensen K, Russell D, Holm S, Ueland T, Fevang B, Hedin U, Yndestad A, Gullestad L, Hansson GK, Biessen EA, Aukrust P (2012)
Increased levels of the homeostatic chemokine CXCL13 in human atherosclerosis - Potential role in plaque stabilization
Atherosclerosis, 224 (1), 266-73
DOI 10.1016/j.atherosclerosis.2012.06.071, PubMed 22840692

Solberg OG, Ueland T, Wergeland R, Dahl CP, Aakhus S, Aukrust P, Gullestad L (2012)
High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis
Scand Cardiovasc J, 46 (5), 278-85
DOI 10.3109/14017431.2012.687836, PubMed 22545649

Ueland T, Aukrust P, Aakhus S, Smith C, Endresen K, Birkeland KI, Gullestad L, Johansen OE (2012)
Activin A and cardiovascular disease in type 2 diabetes mellitus
Diab Vasc Dis Res, 9 (3), 234-7
DOI 10.1177/1479164111431171, PubMed 22234949

Ueland T, Svardal A, Øie E, Askevold ET, Nymoen SH, Bjørndal B, Dahl CP, Gullestad L, Berge RK, Aukrust P (2012)
Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis
Int J Cardiol, 167 (5), 1892-9
DOI 10.1016/j.ijcard.2012.04.150, PubMed 22622056

Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P (2012)
TNF revisited: osteoprotegerin and TNF-related molecules in heart failure
Curr Heart Fail Rep, 9 (2), 92-100
DOI 10.1007/s11897-012-0088-6, PubMed 22453763

Waldum B, Westheim AS, Sandvik L, Flønæs B, Grundtvig M, Gullestad L, Hole T, Os I (2012)
Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry
J Am Coll Cardiol, 59 (4), 371-8
DOI 10.1016/j.jacc.2011.10.864, PubMed 22261159

Yndestad A, Finsen AV, Ueland T, Husberg C, Dahl CP, Øie E, Vinge LE, Sjaastad I, Sandanger Ø, Ranheim T, Dickstein K, Kjekshus J, Damås JK, Fiane AE, Hilfiker-Kleiner D, Lipp M, Gullestad L, Christensen G, Aukrust P (2012)
The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure
PLoS One, 7 (3), e33038
DOI 10.1371/journal.pone.0033038, PubMed 22427939

Publications 2011

Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L (2011)
Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial
Transplantation, 92 (2), 235-43
DOI 10.1097/TP.0b013e31822057f1, PubMed 21677600

Egstrup K, Bergfeldt L, Duris T, Gullestad L, Kochmanski M, Kuśnierz B, Nielsen T, Sawicki S, Aunes-Jansson M, Edvardsson N, Frison L, Johansson S, Berggren A (2011)
QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial
Am J Cardiovasc Drugs, 11 (3), 199-208
DOI 10.2165/11591750-000000000-00000, PubMed 21619383

Fosshaug LE, Berge RK, Beitnes JO, Berge K, Vik H, Aukrust P, Gullestad L, Vinge LE, Øie E (2011)
Krill oil attenuates left ventricular dilatation after myocardial infarction in rats
Lipids Health Dis, 10, 245
DOI 10.1186/1476-511X-10-245, PubMed 22206454

Gullestad L, Pernow J, Bjurö T, Aaberge L, Skårdal R, Kjekshus E, Høglund L, Mellgård AJ, Wahlquist I, Ablad B (2011)
Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease
Scand Cardiovasc J, 46 (1), 23-31
DOI 10.3109/14017431.2011.624195, PubMed 22017530

Nytrøen K, Myers J, Chan KN, Geiran OR, Gullestad L (2011)
Chronotropic responses to exercise in heart transplant recipients: 1-yr follow-up
Am J Phys Med Rehabil, 90 (7), 579-88
DOI 10.1097/PHM.0b013e31821f711d, PubMed 21765276

Tveit A, Flonaes B, Aaser E, Korneliussen K, Froland G, Gullestad L, Grundtvig M (2011)
No impact of atrial fibrillation on mortality risk in optimally treated heart failure patients
Clin Cardiol, 34 (9), 537-42
DOI 10.1002/clc.20939, PubMed 21796642

Ueland T, Aukrust P, Broch K, Aakhus S, Skårdal R, Muntendam P, Gullestad L (2011)
Galectin-3 in heart failure: high levels are associated with all-cause mortality
Int J Cardiol, 150 (3), 361-4
DOI 10.1016/j.ijcard.2011.05.081, PubMed 21641051

Ueland T, Aukrust P, Dahl CP, Husebye T, Solberg OG, Tønnessen T, Aakhus S, Gullestad L (2011)
Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis
J Intern Med, 270 (5), 452-60
DOI 10.1111/j.1365-2796.2011.02393.x, PubMed 21623962

Ueland T, Dahl CP, Gullestad L, Aakhus S, Broch K, Skårdal R, Vermeer C, Aukrust P, Schurgers LJ (2011)
Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure
Clin Sci (Lond), 121 (3), 119-27
DOI 10.1042/CS20100589, PubMed 21294711

Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L (2011)
Osteoprotegerin predicts progression of chronic heart failure: results from CORONA
Circ Heart Fail, 4 (2), 145-52
DOI 10.1161/CIRCHEARTFAILURE.110.957332, PubMed 21216833

Waehre A, Halvorsen B, Yndestad A, Husberg C, Sjaastad I, Nygård S, Dahl CP, Ahmed MS, Finsen AV, Reims H, Louch WE, Hilfiker-Kleiner D, Vinge LE, Roald B, Attramadal H, Lipp M, Gullestad L, Aukrust P, Christensen G (2011)
Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload
PLoS One, 6 (4), e18668
DOI 10.1371/journal.pone.0018668, PubMed 21533157

Øie E, Ueland T, Dahl CP, Bohov P, Berge C, Yndestad A, Gullestad L, Aukrust P, Berge RK (2011)
Fatty acid composition in chronic heart failure: low circulating levels of eicosatetraenoic acid and high levels of vaccenic acid are associated with disease severity and mortality
J Intern Med, 270 (3), 263-72
DOI 10.1111/j.1365-2796.2011.02384.x, PubMed 21466599

Aarones M, Gullestad L, Aakhus S, Ueland T, Skaardal R, Aass H, Wergeland R, Smith HJ, Aukrust P, Kongsgaard E (2011)
Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy
Am Heart J, 161 (6), 1031-7
DOI 10.1016/j.ahj.2010.09.021, PubMed 21641347

Publications 2010

Arora S, Gunther A, Wennerblom B, Ueland T, Andreassen AK, Gude E, Endresen K, Geiran O, Wilhelmsen N, Andersen R, Aukrust P, Gullestad L (2010)
Systemic markers of inflammation are associated with cardiac allograft vasculopathy and an increased intimal inflammatory component
Am J Transplant, 10 (6), 1428-36
DOI 10.1111/j.1600-6143.2010.03118.x, PubMed 20486911

Aukrust P, Halvorsen B, Ueland T, Michelsen AE, Skjelland M, Gullestad L, Yndestad A, Otterdal K (2010)
Activated platelets and atherosclerosis
Expert Rev Cardiovasc Ther, 8 (9), 1297-307
DOI 10.1586/erc.10.92, PubMed 20828352

Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, Halvorsen B, Ueland T (2010)
Tumor necrosis factor superfamily molecules in acute coronary syndromes
Ann Med, 43 (2), 90-103
DOI 10.3109/07853890.2010.523711, PubMed 21039303

Grundtvig M, Gullestad L, Hole T, Flønæs B, Westheim A (2010)
Characteristics, implementation of evidence-based management and outcome in patients with chronic heart failure: results from the Norwegian heart failure registry
Eur J Cardiovasc Nurs, 10 (1), 44-9
DOI 10.1016/j.ejcnurse.2010.04.001, PubMed 20452825

Grundtvig M, Westheim A, Hole T, Flønaes B, Gullestad L, Norwegian Heart Failure Registry (2010)
Warning on diuretic use
J Am Coll Cardiol, 55 (23), 2609-10; author reply 2610
DOI 10.1016/j.jacc.2010.02.039, PubMed 20513605

Gude E, Andreassen AK, Arora S, Gullestad L, Grov I, Hartmann A, Leivestad T, Fiane AE, Geiran OR, Vardal M, Simonsen S (2010)
Acute renal failure early after heart transplantation: risk factors and clinical consequences
Clin Transplant, 24 (6), E207-13
DOI 10.1111/j.1399-0012.2010.01225.x, PubMed 20184627

Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK (2010)
Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation
J Heart Lung Transplant, 29 (6), 641-7
DOI 10.1016/j.healun.2010.01.005, PubMed 20304681

Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH (2010)
Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial
Transplantation, 89 (7), 864-72
DOI 10.1097/TP.0b013e3181cbac2d, PubMed 20061999

Gullestad L, Mortensen SA, Eiskjær H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Iversen M (2010)
Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial
Transplantation, 90 (12), 1581-9
DOI 10.1097/TP.0b013e3181fd01b7, PubMed 21030905

Hallén J, Johansen OE, Birkeland KI, Gullestad L, Aakhus S, Endresen K, Tjora S, Jaffe AS, Atar D (2010)
Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus
Cardiovasc Diabetol, 9, 52
DOI 10.1186/1475-2840-9-52, PubMed 20843304

Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, van Berkel TJ, Biessen EA (2010)
The peripheral blood mononuclear cell microRNA signature of coronary artery disease
Biochem Biophys Res Commun, 394 (3), 792-7
DOI 10.1016/j.bbrc.2010.03.075, PubMed 20230787

Hole T, Grundtvig M, Gullestad L, Flønæs B, Westheim A (2010)
Improved quality of life in Norwegian heart failure patients after follow-up in outpatient heart failure clinics: results from the Norwegian Heart Failure Registry
Eur J Heart Fail, 12 (11), 1247-52
DOI 10.1093/eurjhf/hfq156, PubMed 20847014

Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L, Heart Failure Association of ESC (HFA) (2010)
EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot)
Eur J Heart Fail, 12 (10), 1076-84
DOI 10.1093/eurjhf/hfq154, PubMed 20805094

Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, Vermeer C, Schurgers LJ (2010)
Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis
J Intern Med, 268 (5), 483-92
DOI 10.1111/j.1365-2796.2010.02264.x, PubMed 20804515

Waldum B, Westheim AS, Sandvik L, Flønaes B, Grundtvig M, Gullestad L, Hole T, Os I (2010)
Renal function in outpatients with chronic heart failure
J Card Fail, 16 (5), 374-80
DOI 10.1016/j.cardfail.2010.01.001, PubMed 20447572

Øie E, Ahmed MS, Ueland T, Sikkeland LI, Dahl CP, Hagelin EM, von Lueder T, Edvardsen T, Andreassen AK, Gullestad L, Aukrust P, Yndestad A, Vinge LE, Attramadal H (2010)
Adrenomedullin is increased in alveolar macrophages and released from the lungs into the circulation in severe heart failure
Basic Res Cardiol, 105 (1), 89-98
DOI 10.1007/s00395-009-0070-y, PubMed 19823891

Aarønæs M, Aakhus S, Aass H, Moum T, Wergeland R, Gullestad L, Kongsgård E (2010)
Assessment of response criteria to cardiac resynchronization therapy (CRT) and prediction of response
Scand Cardiovasc J, 44 (6), 337-45
DOI 10.3109/14017431.2010.508537, PubMed 21080864

Publications 2009

Arora S, Aukrust P, Andreassen A, Simonsen S, Gude E, Grov I, Geiran O, Fiane A, Gullestad L (2009)
The prognostic importance of modifiable risk factors after heart transplantation
Am Heart J, 158 (3), 431-6
DOI 10.1016/j.ahj.2009.05.036, PubMed 19699867

Arora S, Aukrust P, Ueland T, Broch K, Simonsen S, Gude E, Fiane AE, Geiran O, Wergeland R, Andreassen AK, Gullestad L (2009)
Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality
Eur J Heart Fail, 11 (10), 1005-13
DOI 10.1093/eurjhf/hfp115, PubMed 19737803

Aukrust P, Ueland T, Gullestad L, Yndestad A (2009)
Testosterone: a novel therapeutic approach in chronic heart failure?
J Am Coll Cardiol, 54 (10), 928-9
DOI 10.1016/j.jacc.2009.05.039, PubMed 19712803

Dahl CP, Husberg C, Gullestad L, Waehre A, Damås JK, Vinge LE, Finsen AV, Ueland T, Florholmen G, Aakhus S, Halvorsen B, Aukrust P, Oie E, Yndestad A, Christensen G (2009)
Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling
Circ Heart Fail, 2 (6), 624-32
DOI 10.1161/CIRCHEARTFAILURE.108.821074, PubMed 19919988

Gjesdal O, Gude E, Arora S, Leivestad T, Andreassen AK, Gullestad L, Aaberge L, Brunvand H, Edvardsen T, Geiran OR, Simonsen S (2009)
Intra-aortic balloon counterpulsation as a bridge to heart transplantation does not impair long-term survival
Eur J Heart Fail, 11 (7), 709-14
DOI 10.1093/eurjhf/hfp078, PubMed 19515719

Gude E, Simonsen S, Geiran OR, Fiane AE, Gullestad L, Arora S, Relbo A, Andreassen AK (2009)
Pulmonary hypertension in heart transplantation: discrepant prognostic impact of pre-operative compared with 1-year post-operative right heart hemodynamics
J Heart Lung Transplant, 29 (2), 216-23
DOI 10.1016/j.healun.2009.08.021, PubMed 19837606

Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschöpe C, Van Bilsen M, Zannad F, McMurray J, Shah AM (2009)
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Eur J Heart Fail, 11 (2), 119-29
DOI 10.1093/eurjhf/hfn043, PubMed 19168509

Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, Januzzi JL (2009)
Osteoprotegerin concentrations and prognosis in acute ischaemic stroke
J Intern Med, 267 (4), 410-7
DOI 10.1111/j.1365-2796.2009.02163.x, PubMed 19895657

Johansen OE, Birkeland KI, Jørgensen AP, Orvik E, Sørgård B, Torjussen BR, Ueland T, Aukrust P, Gullestad L (2009)
Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial
J Diabetes, 1 (3), 182-7
DOI 10.1111/j.1753-0407.2009.00031.x, PubMed 20923537

Kjekshus JK, Torp-Pedersen C, Gullestad L, Køber L, Edvardsen T, Olsen IC, Sjaastad I, Qvigstad E, Skomedal T, Osnes JB, Levy FO (2009)
Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure
Eur J Heart Fail, 11 (8), 771-8
DOI 10.1093/eurjhf/hfp087, PubMed 19567409

McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group (2009)
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
Circulation, 120 (22), 2188-96
DOI 10.1161/CIRCULATIONAHA.109.849117, PubMed 19917888

Sandberg WJ, Otterdal K, Gullestad L, Halvorsen B, Ragnarsson A, Frøland SS, Damås JK, Oie E, Aukrust P, Hansson GK, Yndestad A (2009)
The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis
Thromb Haemost, 102 (4), 704-10
DOI 10.1160/TH08-10-0665, PubMed 19806256

Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM (2009)
Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003
Arterioscler Thromb Vasc Biol, 29 (6), 975-80
DOI 10.1161/ATVBAHA.109.184101, PubMed 19325145

Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg WJ, Paulsson-Berne G, Pedersen TM, Folkersen L, Gullestad L, Oie E, Hansson GK, Aukrust P (2009)
Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis
Arterioscler Thromb Vasc Biol, 29 (8), 1228-34
DOI 10.1161/ATVBAHA.109.189761, PubMed 19498175

Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Frøland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Øie E, Gullestad L, Aukrust P (2009)
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure
Eur Heart J, 30 (10), 1229-36
DOI 10.1093/eurheartj/ehp088, PubMed 19329498

Publications 2008

Arora S, Jenum PA, Aukrust P, Rollag H, Andreassen AK, Simonsen S, Guide E, Fiane AE, Geiran O, Gullestad L (2008)
Pre-transplant Toxoplasma gondii seropositivlty among heart transplant recipients and mortality - Reply
J. Am. Coll. Cardiol., 51 (18), 1827-1828

Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, Gullestad L, Damås JK (2008)
Chemokines and cardiovascular risk
Arterioscler Thromb Vasc Biol, 28 (11), 1909-19
DOI 10.1161/ATVBAHA.107.161240, PubMed 18669888

Aukrust P, Otterdal K, Yndestad A, Sandberg WJ, Smith C, Ueland T, Øie E, Damås JK, Gullestad L, Halvorsen B (2008)
The complex role of T-cell-based immunity in atherosclerosis
Curr Atheroscler Rep, 10 (3), 236-43
DOI 10.1007/s11883-008-0037-8, PubMed 18489852

Breland UM, Halvorsen B, Hol J, Øie E, Paulsson-Berne G, Yndestad A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg WJ, Frøland SS, Haraldsen G, Gullestad L, Damås JK, Hansson GK, Aukrust P (2008)
A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins
Arterioscler Thromb Vasc Biol, 28 (5), 1005-11
DOI 10.1161/ATVBAHA.108.162305, PubMed 18276907

Dahl CP, Gullestad L, Fevang B, Holm AM, Landrø L, Vinge LE, Fiane AE, Sandberg WJ, Otterdal K, Frøland SS, Damås JK, Halvorsen B, Aukrust P, Øie E, Yndestad A (2008)
Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure
Eur J Heart Fail, 10 (4), 352-9
DOI 10.1016/j.ejheart.2008.02.010, PubMed 18353719

Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Øie E, Aukrust P (2008)
Atherosclerotic plaque stability--what determines the fate of a plaque?
Prog Cardiovasc Dis, 51 (3), 183-94
DOI 10.1016/j.pcad.2008.09.001, PubMed 19026853

Husberg C, Nygård S, Finsen AV, Damås JK, Frigessi A, Oie E, Waehre A, Gullestad L, Aukrust P, Yndestad A, Christensen G (2008)
Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure
J Mol Cell Cardiol, 45 (2), 261-9
DOI 10.1016/j.yjmcc.2008.05.009, PubMed 18585734

Sandberg WJ, Halvorsen B, Yndestad A, Smith C, Otterdal K, Brosstad FR, Frøland SS, Olofsson PS, Damås JK, Gullestad L, Hansson GK, Oie E, Aukrust P (2008)
Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis
Circ Res, 104 (1), 60-8
DOI 10.1161/CIRCRESAHA.108.188078, PubMed 19023130

Smith C, Halvorsen B, Otterdal K, Waehre T, Yndestad A, Fevang B, Sandberg WJ, Breland UM, Frøland SS, Oie E, Gullestad L, Damås JK, Aukrust P (2008)
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins
Cardiovasc Res, 79 (1), 195-203
DOI 10.1093/cvr/cvn071, PubMed 18339644

Publications 2007

Arora S, Andreassen A, Simonsen S, Gude E, Dahl C, Skaardal R, Hoel I, Geiran O, Gullestad L (2007)
Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy
Transplantation, 84 (2), 149-54
DOI 10.1097/01.tp.0000268810.61393.2c, PubMed 17667805

Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A, Ueland T, Geiran O, Andreassen A (2007)
Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation
Transplantation, 83 (10), 1308-15
DOI 10.1097/01.tp.0000263338.39555.21, PubMed 17519779

Arora S, Jenum PA, Aukrust P, Rollag H, Andreassen AK, Simonsen S, Gude E, Fiane AE, Geiran O, Gullestad L (2007)
Pre-transplant Toxoplasma gondii seropositivity among heart transplant recipients is associated with an increased risk of all-cause and cardiac mortality
J Am Coll Cardiol, 50 (20), 1967-72
DOI 10.1016/j.jacc.2007.07.068, PubMed 17996562

Aukrust P, Yndestad A, Damås JK, Ueland T, Øie E, Gullestad L (2007)
Potential mechanisms of benefit with thalidomide in chronic heart failure
Am J Cardiovasc Drugs, 7 (2), 127-34
DOI 10.2165/00129784-200707020-00004, PubMed 17503883

Aukrust P, Yndestad A, Sandberg WJ, Gullestad L, Damås JK (2007)
T cells in coronary artery disease: different effects of different T-cell subsets
J Am Coll Cardiol, 50 (15), 1459-61
DOI 10.1016/j.jacc.2007.06.041, PubMed 17919565

Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damås JK (2007)
Chemokines in cardiovascular risk prediction
Thromb Haemost, 97 (5), 748-54
DOI 10.1160/TH07-01-0029, PubMed 17479185

Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B (2007)
Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization
Circulation, 115 (8), 972-80
DOI 10.1161/CIRCULATIONAHA.106.665893, PubMed 17283255

Gullestad L, Madsen S (2007)
[Diuretics not the first-choice-drug in chronic heart failure]
Tidsskr Nor Laegeforen, 127 (5), 621; author reply 621
PubMed 17332822

Gullestad L, Oie E, Ueland T, Yndestad A, Aukrust P (2007)
The role of statins in heart failure
Fundam Clin Pharmacol, 21 Suppl 2, 35-40
DOI 10.1111/j.1472-8206.2007.00538.x, PubMed 18001320

Havik OE, Sivertsen B, Relbo A, Hellesvik M, Grov I, Geiran O, Andreassen AK, Simonsen S, Gullestad L (2007)
Depressive symptoms and all-cause mortality after heart transplantation
Transplantation, 84 (1), 97-103
DOI 10.1097/01.tp.0000268816.90672.a0, PubMed 17627244

Johansen OE, Birkeland KI, Orvik E, Flesland Ø, Wergeland R, Ueland T, Smith C, Endresen K, Aukrust P, Gullestad L (2007)
Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects
Scand J Clin Lab Invest, 67 (3), 306-16
DOI 10.1080/00365510601045088, PubMed 17454845

Johansen OE, Bjurö T, Endresen K, Blaasaas KG, Birkeland K, Aakhus S, Gullestad L (2007)
Heart rate adjustments and analysis of recovery patterns of ST-segment depression in type 2 diabetes
Int J Cardiol, 127 (1), 129-32
DOI 10.1016/j.ijcard.2007.04.022, PubMed 17532067

Johansen OE, Gullestad L, Blaasaas KG, Orvik E, Birkeland KI (2007)
Effects of structured hospital-based care compared with standard care for Type 2 diabetes-The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial
Diabet Med, 24 (9), 1019-27
DOI 10.1111/j.1464-5491.2007.02198.x, PubMed 17509068

Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ et al. (2007)
Rosuvastatin in older patients with systolic heart failure
N Engl J Med, 357 (22), 2248-61
DOI 10.1056/NEJMoa0706201, PubMed 17984166

Otterdal K, Andreassen AK, Yndestad A, Oie E, Sandberg WJ, Dahl CP, Pedersen TM, Ueland T, Gullestad L, Brosstad FR, Aukrust P, Damås JK (2007)
Raised LIGHT levels in pulmonary arterial hypertension: potential role in thrombus formation
Am J Respir Crit Care Med, 177 (2), 202-7
DOI 10.1164/rccm.200703-506OC, PubMed 17962639

Simonsen S, Andreassen AK, Gullestad L, Leivestad T, Fiane AE, Geiran OR (2007)
[Survival after heart transplantation in Norway]
Tidsskr Nor Laegeforen, 127 (7), 865-8
PubMed 17435806

Sivertsen B, Relbo A, Gullestad L, Hellesvik M, Grov I, Andreassen A, Simonsen S, Geiran O, Havik OE (2007)
[Self-assessed health and psychological symptoms after heart transplantation]
Tidsskr Nor Laegeforen, 127 (24), 3198-201
PubMed 18084359

Yndestad A, Damås JK, Øie E, Ueland T, Gullestad L, Aukrust P (2007)
Role of inflammation in the progression of heart failure
Curr Cardiol Rep, 9 (3), 236-41
PubMed 17470337

Publications 2006

Aukrust P, Yndestad A, Ueland T, Damås JK, Frøland SS, Gullestad L (2006)
The role of intravenous immunoglobulin in the treatment of chronic heart failure
Int J Cardiol, 112 (1), 40-5
DOI 10.1016/j.ijcard.2006.05.015, PubMed 16893578

Aukrust P, Yndestad A, Ueland T, Damås JK, Gullestad L (2006)
Anti-inflammatory trials in chronic heart failure
Heart Fail Monit, 5 (1), 2-9
PubMed 16547529

Damås JK, Smith C, Øie E, Fevang B, Halvorsen B, Waehre T, Boullier A, Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, Taskén K, Frøland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P (2006)
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization
Arterioscler Thromb Vasc Biol, 27 (3), 614-20
DOI 10.1161/01.ATV.0000255581.38523.7c, PubMed 17170367

Holm T, Ueland T, Halvorsen B, Hognestad A, Holm AG, Wergeland R, Gullestad L, Aukrust P, Kjekshus J (2006)
A protective anti-inflammatory phenotype in high-risk individuals who do not develop coronary artery disease
J Am Coll Cardiol, 47 (5), 1085-6
DOI 10.1016/j.jacc.2005.11.042, PubMed 16516099

Johansen OE, Birkeland KI, Brustad E, Aaser E, Lindahl AK, Midha R, Ueland T, Aukrust P, Gullestad L (2006)
Undiagnosed dysglycaemia and inflammation in cardiovascular disease
Eur J Clin Invest, 36 (8), 544-51
DOI 10.1111/j.1365-2362.2006.01679.x, PubMed 16893376

Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P (2006)
Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization
Arterioscler Thromb Vasc Biol, 26 (4), 857-63
DOI 10.1161/01.ATV.0000204334.48195.6a, PubMed 16424351

Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Frøland SS, Hansson GK, Aukrust P (2006)
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation
J Am Coll Cardiol, 48 (8), 1591-9
DOI 10.1016/j.jacc.2006.06.060, PubMed 17045893

Ueland T, Aukrust P, Damas JK, Gullestad L, Yndestad A (2006)
The tumor necrosis factor superfamily in heart failure
Future Cardiol, 2 (1), 101-11
DOI 10.2217/14796678.2.1.101, PubMed 19804137

Ueland T, Espevik T, Kjekshus J, Gullestad L, Omland T, Squire IB, Frøland SS, Mollnes TE, Dickstein K, Aukrust P (2006)
Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction
J Card Fail, 12 (8), 659-63
DOI 10.1016/j.cardfail.2006.07.002, PubMed 17045187

Ueland T, Gullestad L, Simonsen S, Endresen K, Scott H, Frøland SS, Geiran O, Fiane AE, Aukrust P (2006)
Decreased endomyocardial RANKL expression in transplant coronary artery disease
Transplantation, 81 (10), 1467-70
DOI 10.1097/01.tp.0000209413.45179.f6, PubMed 16732187

Ueland T, Vissers MN, Wiegman A, Rodenburg J, Hutten B, Gullestad L, Ose L, Rifai N, Ridker PM, Kastelein JJ, Aukrust P, Semb AG (2006)
Increased inflammatory markers in children with familial hypercholesterolaemia
Eur J Clin Invest, 36 (3), 147-52
DOI 10.1111/j.1365-2362.2006.01613.x, PubMed 16506958

van Veldhuisen DJ, Aass H, El Allaf D, Dunselman PH, Gullestad L, Halinen M, Kjekshus J, Ohlsson L, Wedel H, Wikstrand J, MERIT-HF Study Group (2006)
Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study
Eur J Heart Fail, 8 (5), 539-46
DOI 10.1016/j.ejheart.2006.01.015, PubMed 16567126

Waehre T, Damås JK, Pedersen TM, Gullestad L, Yndestad A, Andreassen AK, Frøland SS, Semb AG, Hansteen V, Gjertsen E, Ueland T, Brosstad F, Solum NO, Aukrust P (2006)
Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study
J Thromb Haemost, 4 (10), 2140-7
DOI 10.1111/j.1538-7836.2006.02131.x, PubMed 16856976

Yndestad A, Damås JK, Oie E, Ueland T, Gullestad L, Aukrust P (2006)
Systemic inflammation in heart failure--the whys and wherefores
Heart Fail Rev, 11 (1), 83-92
DOI 10.1007/s10741-006-9196-2, PubMed 16819581

Publications 2005

Aukrust P, Gullestad L, Ueland T, Damås JK, Yndestad A (2005)
Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications
Ann Med, 37 (2), 74-85
DOI 10.1080/07853890510007232, PubMed 16026115

Aukrust P, Yndestad A, Smith C, Sandberg WJ, Ueland T, Waehre T, Halvorsen B, Gullestad L, Damås JK (2005)
Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation
Expert Opin Pharmacother, 6 (13), 2169-80
DOI 10.1517/14656566.6.13.2169, PubMed 16218879

Aukrust P, Yndestad A, Waehre T, Gullestad L, Halvorsen B, Damås JK (2005)
Inflammation in coronary artery disease: potential role for immunomodulatory therapy
Expert Rev Cardiovasc Ther, 3 (6), 1111-24
DOI 10.1586/14779072.3.6.1111, PubMed 16293001

Fiane AE, Ueland T, Simonsen S, Scott H, Endresen K, Gullestad L, Geiran OR, Haraldsen G, Heggelund L, Andreassen AK, Wergeland R, Frøland S, Aukrust P, Mollnes TE (2005)
Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation
Eur Heart J, 26 (16), 1660-5
DOI 10.1093/eurheartj/ehi198, PubMed 15821010

Gullestad L, Aukrust P (2005)
Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches
Am J Cardiol, 95 (11A), 17C-23C; discussion 38C-40C
DOI 10.1016/j.amjcard.2005.03.008, PubMed 15925560

Gullestad L, Kjekshus J, Damås JK, Ueland T, Yndestad A, Aukrust P (2005)
Agents targeting inflammation in heart failure
Expert Opin Investig Drugs, 14 (5), 557-66
DOI 10.1517/13543784.14.5.557, PubMed 15926863

Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, Følling M, Hodt A, Skårdal R, Kjekshus J, Andreassen A, Kjekshus E, Wergeland R, Yndestad A, Frøland SS, Semb AG, Aukrust P (2005)
Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study
Circulation, 112 (22), 3408-14
DOI 10.1161/CIRCULATIONAHA.105.564971, PubMed 16301340

Gullestad L, Wikstrand J, Deedwania P, Hjalmarson A, Egstrup K, Elkayam U, Gottlieb S, Rashkow A, Wedel H, Bermann G, Kjekshus J, MERIT-HF Study Group (2005)
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)
J Am Coll Cardiol, 45 (2), 252-9
DOI 10.1016/j.jacc.2004.10.032, PubMed 15653024

Scholz H, Sandberg W, Damås JK, Smith C, Andreassen AK, Gullestad L, Frøland SS, Yndestad A, Aukrust P, Halvorsen B (2005)
Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis
Circulation, 112 (14), 2121-9
DOI 10.1161/CIRCULATIONAHA.105.544676, PubMed 16186421

Ueland T, Aukrust P, Yndestad A, Otterdal K, Frøland SS, Dickstein K, Kjekshus J, Gullestad L, Damås JK (2005)
Soluble CD40 ligand in acute and chronic heart failure
Eur Heart J, 26 (11), 1101-7
DOI 10.1093/eurheartj/ehi132, PubMed 15716285

Ueland T, Kjekshus J, Frøland SS, Omland T, Squire IB, Gullestad L, Dickstein K, Aukrust P (2005)
Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients
J Am Coll Cardiol, 46 (11), 2018-21
DOI 10.1016/j.jacc.2005.08.039, PubMed 16325035

Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P (2005)
Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure
Circulation, 111 (19), 2461-8
DOI 10.1161/01.CIR.0000165119.62099.14, PubMed 15883214

Publications 2004

Aukrust P, Yndestad A, Damås JK, Gullestad L (2004)
Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin
Autoimmun Rev, 3 (3), 221-7
DOI 10.1016/S1568-9972(03)00103-4, PubMed 15110235

Aukrust P, Yndestad A, Damås JK, Gullestad L (2004)
Therapeutic potential of anticytokine therapy in congestive heart failure
Am J Cardiovasc Drugs, 4 (3), 169-77
DOI 10.2165/00129784-200404030-00004, PubMed 15134469

Bjurö T, Gullestad L, Endresen K, Nordlander M, Malm A, Höglund L, Wahlqvist I, Pernow J (2004)
Evaluation of ST-segment changes during and after maximal exercise tests in one-, two- and three-vessel coronary artery disease
Scand Cardiovasc J, 38 (5), 270-7
DOI 10.1080/14017430410021606, PubMed 15513309

Gullestad L, Madsen S (2004)
[Modern diagnosis and treatment of heart failure]
Tidsskr Nor Laegeforen, 124 (8), 1107-10
PubMed 15114390

Gullestad L, Myers J, Edvardsen T, Kjekshus J, Geiran O, Simonsen S (2004)
Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipients
Am Heart J, 147 (1), 49-54
DOI 10.1016/j.ahj.2003.07.013, PubMed 14691418

Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, Holm T, Andreassen AK, Kjekshus JK (2004)
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation
Clin Cardiol, 27 (4), 199-203
DOI 10.1002/clc.4960270405, PubMed 15119693

Hole T, Frøland G, Gullestad L, Offstad J, Skjaerpe T (2004)
Metoprolol CR/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure
Echocardiography, 21 (3), 215-23
DOI 10.1111/j.0742-2822.2004.03102.x, PubMed 15053783

Larsson L, Mobini R, Aukrust P, Gullestad L, Wallukat G, Waagstein F, Fu M (2004)
Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody
Autoimmunity, 37 (6-7), 489-93
DOI 10.1080/08916930400011684, PubMed 15621576

Smith C, Yndestad A, Halvorsen B, Ueland T, Waehre T, Otterdal K, Scholz H, Endresen K, Gullestad L, Frøland SS, Damås JK, Aukrust P (2004)
Potential anti-inflammatory role of activin A in acute coronary syndromes
J Am Coll Cardiol, 44 (2), 369-75
DOI 10.1016/j.jacc.2004.03.069, PubMed 15261933

Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L (2004)
Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion
Am J Cardiol, 93 (6), 780-2
DOI 10.1016/j.amjcard.2003.12.009, PubMed 15019894

Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P (2004)
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction
J Am Coll Cardiol, 44 (10), 1970-6
DOI 10.1016/j.jacc.2004.06.076, PubMed 15542278

Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Frøland SS, Semb AG, Aukrust P, Damås JK (2004)
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors
Circulation, 109 (16), 1966-72
DOI 10.1161/01.CIR.0000125700.33637.B1, PubMed 15051633

Yndestad A, Ueland T, Øie E, Florholmen G, Halvorsen B, Attramadal H, Simonsen S, Frøland SS, Gullestad L, Christensen G, Damås JK, Aukrust P (2004)
Elevated levels of activin A in heart failure: potential role in myocardial remodeling
Circulation, 109 (11), 1379-85
DOI 10.1161/01.CIR.0000120704.97934.41, PubMed 14993131

Publications 2003

Aukrust P, Damås JK, Gullestad L (2003)
Immunomodulating therapy: new treatment modality in congestive heart failure
Congest Heart Fail, 9 (2), 64-9
PubMed 12671336

Damås JK, Waehre T, Yndestad A, Otterdal K, Hognestad A, Solum NO, Gullestad L, Frøland SS, Aukrust P (2003)
Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets
Circulation, 107 (21), 2670-6
DOI 10.1161/01.CIR.0000070542.18001.87, PubMed 12742982

Gullestad L, Bjurø T, Aaberge L, Apelland T, Skårdal R, Kjekshus E, Nordlander M, Ablad B, Pernow J (2003)
The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris
Eur Heart J, 24 (12), 1120-7
DOI 10.1016/S0195-668X(03)00209-4, PubMed 12804926

Gullestad L, Kjekshus J (2003)
[Use of beta-blockaders in heart failure]
Tidsskr Nor Laegeforen, 123 (5), 651-2
PubMed 12683197

Holm T, Damås JK, Holven K, Nordøy I, Brosstad FR, Ueland T, Währe T, Kjekshus J, Frøland SS, Eiken HG, Solum NO, Gullestad L, Nenseter M, Aukrust P (2003)
CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells
J Thromb Haemost, 1 (2), 257-62
DOI 10.1046/j.1538-7836.2003.00065.x, PubMed 12871498

Myers J, Geiran O, Simonsen S, Ghuyoumi A, Gullestad L (2003)
Clinical and exercise test determinants of survival after cardiac transplantation
Chest, 124 (5), 2000-5
DOI 10.1378/chest.124.5.2000, PubMed 14605079

Myers J, Gullestad L, Bellin D, Ross H, Vagelos R, Fowler M (2003)
Physical activity patterns and exercise performance in cardiac transplant recipients
J Cardiopulm Rehabil, 23 (2), 100-6
PubMed 12668931

Ronnevig M, Bjorsvik E, Gullestad L, Forfang K (2003)
A descriptive study of early nonspecific chest pain after PTCA: important area for the acute health care personnel
Heart Lung, 32 (4), 241-9
DOI 10.1016/S0147-9563(03)00024-4, PubMed 12891164

Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Froland SS, Kastelein JJP, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AFH (2003)
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Downregulatory effect of statin therapy
J. Am. Coll. Cardiol., 41 (2), PII S0735-1097(2)02718-3-279

Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Frøland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF (2003)
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy
J Am Coll Cardiol, 41 (2), 275-9
PubMed 12535822

Ueland T, Sikkeland LI, Yndestad A, Eiken HG, Holm T, Guevara C, Haug T, Endresen K, Frøland SS, Gullestad L, Andreassen AK, Geiran O, Simonsen S, Aukrust P (2003)
Myocardial gene expression of inflammatory cytokines after heart transplantation in relation to the development of transplant coronary artery disease
Am J Cardiol, 92 (6), 715-7
DOI 10.1016/S0002-9149(03)00836-1, PubMed 12972116

Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Frøland SS, Semb AG, Aukrust P (2003)
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease
J Am Coll Cardiol, 41 (9), 1460-7
DOI 10.1016/S0735-1097(03)00263-8, PubMed 12742282

Yndestad A, Holm AM, Müller F, Simonsen S, Frøland SS, Gullestad L, Aukrust P (2003)
Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure
Cardiovasc Res, 60 (1), 141-6
DOI 10.1016/S0008-6363(03)00362-6, PubMed 14522416

Publications 2002

Damås JK, Waehre T, Yndestad A, Ueland T, Müller F, Eiken HG, Holm AM, Halvorsen B, Frøland SS, Gullestad L, Aukrust P (2002)
Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects
Circulation, 106 (1), 36-42
DOI 10.1161/01.CIR.0000020001.09990.90, PubMed 12093767

Gottlieb SS, Fisher ML, Kjekshus J, Deedwania P, Gullestad L, Vitovec J, Wikstrand J, MERIT-HF Investigators (2002)
Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
Circulation, 105 (10), 1182-8
DOI 10.1161/hc1002.105180, PubMed 11889011

Gullestad L, Semb AG, Holt E, Skårdal R, Ueland T, Yndestad A, Frøland SS, Aukrust P (2002)
Effect of thalidomide in patients with chronic heart failure
Am Heart J, 144 (5), 847-50
DOI 10.1067/mhj.2002.125628, PubMed 12422154

Holm T, Aukrust P, Aagaard E, Ueland T, Haugstad TS, Kjekshus J, Simonsen S, Frøland SS, Gullestad L, Andreassen AK (2002)
Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension
Transplantation, 74 (10), 1395-400
DOI 10.1097/01.TP.0000036055.59814.4C, PubMed 12451238

Lund TM, Torsvik H, Falch D, Christophersen B, Skardal R, Gullestad L (2002)
Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease
Am. J. Cardiol., 90 (7), PII S0002-9149(02)02614-0-+

Lund TM, Torsvik H, Falch D, Christophersen B, Skårdal R, Gullestad L (2002)
Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease
Am J Cardiol, 90 (7), 784-6
PubMed 12356401

Waehre T, Halvorsen B, Damås JK, Yndestad A, Brosstad F, Gullestad L, Kjekshus J, Frøland SS, Aukrust P (2002)
Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10
Eur J Clin Invest, 32 (11), 803-10
DOI 10.1046/j.1365-2362.2002.01069.x, PubMed 12423320

Yndestad A, Damas JK, Eiken HG, Holm T, Haug T, Simonsen S, Froland SS, Gullestad L, Aukrust P (2002)
Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure
Cardiovasc. Res., 54 (1), PII S0008-6363(02)00238-9-182

Yndestad A, Damås JK, Geir Eiken H, Holm T, Haug T, Simonsen S, Frøland SS, Gullestad L, Aukrust P (2002)
Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure
Cardiovasc Res, 54 (1), 175-82
PubMed 12062373

Publications 2001

Aukrust P, Berge RK, Ueland T, Aaser E, Damås JK, Wikeby L, Brunsvig A, Müller F, Forfang K, Frøland SS, Gullestad L (2001)
Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes
J Am Coll Cardiol, 37 (2), 485-91
DOI 10.1016/S0735-1097(00)01110-4, PubMed 11216967

Aukrust P, Damås JK, Gullestad L, Frøland SS (2001)
Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets
Clin Exp Immunol, 124 (3), 343-5
DOI 10.1046/j.1365-2249.2001.01527.x, PubMed 11472392

Aukrust P, Gullestad L, Lappegård KT, Ueland T, Aass H, Wikeby L, Simonsen S, Frøland SS, Mollnes TE (2001)
Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment
Circulation, 104 (13), 1494-500
DOI 10.1161/hc3801.096353, PubMed 11571242

Aukrust P, Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Froland SS (2001)
Increase in anti-inflammatory cytokine levels in chronic heart failure: A measure of treatment success or failure? Response
Circulation, 104 (18), E97-E98

Aukrust P, Waehre T, Damås JK, Gullestad L, Solum NO (2001)
Inflammatory role of platelets in acute coronary syndromes
Heart, 86 (6), 605-6
DOI 10.1136/heart.86.6.605, PubMed 11711447

Dahle MG, Gullestad L, Simonsen S (2001)
Plasma N-terminal proatrial natriuretic factor can predict normal pulmonary capillary wedge pressure in cardiac transplant recipients
Scand Cardiovasc J, 35 (6), 367-71
DOI 10.1080/14017430152754844, PubMed 11837515

Damås JK, Aukrust P, Ueland T, Odegaard A, Eiken HG, Gullestad L, Sejersted OM, Christensen G (2001)
Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes
Basic Res Cardiol, 96 (4), 345-52
DOI 10.1007/s003950170042, PubMed 11518190

Damås JK, Gullestad L, Aukrust P (2001)
Cytokines as new treatment targets in chronic heart failure
Curr Control Trials Cardiovasc Med, 2 (6), 271-277
DOI 10.1186/CVM-2-6-271, PubMed 11806813

Damås JK, Gullestad L, Aass H, Simonsen S, Fjeld JG, Wikeby L, Ueland T, Eiken HG, Frøland SS, Aukrust P (2001)
Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin
J Am Coll Cardiol, 38 (1), 187-93
DOI 10.1016/S0735-1097(01)01335-3, PubMed 11451272

Eiken HG, Øie E, Damås JK, Yndestad A, Bjerkeli V, Aass H, Simonsen S, Geiran OR, Tønnessen T, Christensen G, Frøland SS, Gullestad L, Attramadal H, Aukrust P (2001)
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure
Eur J Clin Invest, 31 (5), 389-97
DOI 10.1046/j.1365-2362.2001.00795.x, PubMed 11380590

Gullestad L, Aukrust P (2001)
The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets
Heart Fail Monit, 2 (1), 8-13
PubMed 12634893

Gullestad L, Manhenke C, Aarsland T, Skårdal R, Fagertun H, Wikstrand J, Kjekshus J (2001)
Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial
Eur J Heart Fail, 3 (4), 463-8
DOI 10.1016/S1388-9842(01)00146-5, PubMed 11511433

Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Frøland SS, Aukrust P (2001)
Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF)
Am Heart J, 141 (3), 418-21
DOI 10.1067/mhj.2001.112785, PubMed 11231439

Gullestad L, Aass H, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Wikeby L, Nitter-Hauge S, Fjeld JG, Lien E, Ueland T, Frøland SS, Aukrust P (2001)
[Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin]
Tidsskr Nor Laegeforen, 121 (16), 1902-7
PubMed 11488180

Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Frøland SS, Aukrust P (2001)
Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure
Circulation, 103 (2), 220-5
PubMed 11208680

Holm T, Andreassen AK, Aukrust P, Andersen K, Geiran OR, Kjekshus J, Simonsen S, Gullestad L (2001)
Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients
Eur Heart J, 22 (5), 428-36
DOI 10.1053/euhj.2000.2369, PubMed 11207085

Holm T, Andreassen AK, Ueland T, Kjekshus J, Frøland SS, Kjekshus E, Simonsen S, Aukrust P, Gullestad L (2001)
Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients
Am J Cardiol, 87 (6), 815-8, A9
DOI 10.1016/S0002-9149(00)01516-2, PubMed 11249916

Holm T, Berge RK, Andreassen AK, Ueland T, Kjekshus J, Simonsen S, Frøland S, Gullestad L, Aukrust P (2001)
Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients
Transplantation, 72 (4), 706-11
DOI 10.1097/00007890-200108270-00025, PubMed 11544435

Holven KB, Holm T, Aukrust P, Christensen B, Kjekshus J, Andreassen AK, Gullestad L, Hagve TA, Svilaas A, Ose L, Nenseter MS (2001)
Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects
Am J Med, 110 (7), 536-42
DOI 10.1016/S0002-9343(01)00696-9, PubMed 11343667

Publications 2000

Damås JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, Ueland T, Tonnessen T, Geiran OR, Aass H, Simonsen S, Christensen G, Froland SS, Attramadal H, Gullestad L, Aukrust P (2000)
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure
Cardiovasc Res, 47 (4), 778-87
DOI 10.1016/S0008-6363(00)00142-5, PubMed 10974226

Damås JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Frøland SS, Aukrust P (2000)
CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes
Cardiovasc Res, 45 (2), 428-36
DOI 10.1016/S0008-6363(99)00262-X, PubMed 10728363

Gullestad L, Jorgensen B, Bjuro T, Pernow J, Lundberg JM, Dota CD, Hall C, Simonsen S, Ablad B (2000)
Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease
Circulation, 102 (9), 987-93
DOI 10.1161/01.CIR.102.9.987, PubMed 10961962

Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P (2000)
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group
JAMA, 283 (10), 1295-302
DOI 10.1001/jama.283.10.1295, PubMed 10714728

Holm T, Aukrust P, Andreassen AK, Ueland T, Brosstad F, Frøland SS, Simonsen S, Gullestad L (2000)
Peripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines
Clin Transplant, 14 (3), 218-25
DOI 10.1034/j.1399-0012.2000.140307.x, PubMed 10831080

Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB (2000)
Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited
Am Heart J, 139 (1 Pt 1), 78-84
PubMed 10618566

Publications 1999

Aukrust P, Gullestad L, Frøland SS (1999)
Is apoptosis an important pathogenic factor in cardiovascular disease?
Eur J Clin Invest, 29 (5), 369-71
PubMed 10354192

Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L (1999)
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes
Circulation, 100 (6), 614-20
DOI 10.1161/01.CIR.100.6.614, PubMed 10441098

Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L (1999)
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Am J Cardiol, 83 (3), 376-82
DOI 10.1016/S0002-9149(98)00872-8, PubMed 10072227

Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Frøland SS, Fowler M (1999)
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure
J Am Coll Cardiol, 34 (7), 2061-7
DOI 10.1016/S0735-1097(99)00495-7, PubMed 10588224

Gullestad L, Bjørnerheim R, Offstad J, Endresen K, Forfang K, Kjekshus J, Hansteen V (1999)
[Current use of beta-blockers in coronary artery disease]
Tidsskr Nor Laegeforen, 119 (1), 24-8
PubMed 10025200

Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S (1999)
Interaction between lovastatin and cyclosporine A after heart and kidney transplantation
Transplant Proc, 31 (5), 2163-5
DOI 10.1016/S0041-1345(99)00295-X, PubMed 10456002

Gullestad L, Simonsen S, Ueland T, Holm T, Aass H, Andreassen AK, Madsen S, Geiran O, Frøland SS, Aukrust P (1999)
Possible role of proinflammatory cytokines in heart allograft coronary artery disease
Am J Cardiol, 84 (9), 999-1003
DOI 10.1016/S0002-9149(99)00487-7, PubMed 10569653

Kjekshus J, Gullestad L (1999)
Heart rate as a therapeutic target in heart failure
Eur. Heart J. Suppl., 1 (H), H64-H69

Simonsen S, Andreassen AK, Gullestad L, Lindberg H, Seem E, Geiran OR (1999)
[Heart transplantation in Norway]
Tidsskr Nor Laegeforen, 119 (23), 3447-50
PubMed 10553344

Publications 1998

Andreassen AK, Gullestad L, Endresen K (1998)
[Thrombolytic treatment in acute myocardial infarction. Choice of preparations in Norwegian hospitals]
Tidsskr Nor Laegeforen, 118 (17), 2630-1
PubMed 9673511

Andreassen AK, Gullestad L, Holm T, Simonsen S, Kvernebo K (1998)
Endothelium-dependent vasodilation of the skin microcirculation in heart transplant recipients
Clin Transplant, 12 (4), 324-32
PubMed 9686327

Andreassen AK, Kirkebøen KA, Gullestad L, Simonsen S, Kvernebo K (1998)
Effect of heart transplantation on impaired peripheral microvascular perfusion and reactivity in congestive heart failure
Int J Cardiol, 65 (1), 33-40
DOI 10.1016/S0167-5273(98)00103-X, PubMed 9699928

Andreassen AK, Kvernebo K, Jørgensen B, Simonsen S, Kjekshus J, Gullestad L (1998)
Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation
Am Heart J, 136 (2), 320-8
DOI 10.1053/hj.1998.v136.89731, PubMed 9704697

Andreassen AK, Nordøy I, Simonsen S, Ueland T, Müller F, Frøland SS, Gullestad L, Aukrust P (1998)
Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation
Am J Cardiol, 81 (5), 604-8
DOI 10.1016/S0002-9149(97)00972-7, PubMed 9514458

Aukrust P, Ueland T, Müller F, Andreassen AK, Nordøy I, Aas H, Kjekshus J, Simonsen S, Frøland SS, Gullestad L (1998)
Elevated circulating levels of C-C chemokines in patients with congestive heart failure
Circulation, 97 (12), 1136-43
DOI 10.1161/01.CIR.97.12.1136, PubMed 9537339

Gullestad L, Birkeland K, Bjønerheim R, Djøseland O, Trygstad O, Simonsen S (1998)
Exercise capacity and hormonal response in adults with childhood onset growth hormone deficiency during long-term somatropin treatment
Growth Horm IGF Res, 8 (5), 377-84
DOI 10.1016/S1096-6374(98)80307-9, PubMed 10984298

Gullestad L, Haywood G, Aass H, Ross H, Yee G, Ueland T, Geiran O, Kjekshus J, Simonsen S, Bishopric N, Fowler M (1998)
Angiotensin II receptor subtype AT1 and AT2 expression after heart transplantation
Cardiovasc Res, 38 (2), 340-7
DOI 10.1016/S0008-6363(98)00015-7, PubMed 9709394

Gullestad L, Myers J, Ross H, Rickenbacher P, Slauson S, Bellin D, Do D, Vagelos R, Fowler M (1998)
Serial exercise testing and prognosis in selected patients considered for cardiac transplantation
Am Heart J, 135 (2 Pt 1), 221-9
DOI 10.1016/S0002-8703(98)70085-7, PubMed 9489968

Gullestad L, Aass H, Ross H, Ueland T, Geiran O, Kjekshus J, Simonsen S, Fowler M, Kobilka B (1998)
Neuropeptide Y receptor 1 (NPY-Y1) expression in human heart failure and heart transplantation
J Auton Nerv Syst, 70 (1-2), 84-91
DOI 10.1016/S0165-1838(98)00032-0, PubMed 9686908

Myers J, Gullestad L (1998)
The role of exercise testing and gas-exchange measurement in the prognostic assessment of patients with heart failure
Curr Opin Cardiol, 13 (3), 145-55
PubMed 9649936

Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H, Fowler MB (1998)
Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure
Ann Intern Med, 129 (4), 286-93
PubMed 9729181

Risum O, Arafa O, Svennevig JL, Levorstad K, Abdelnoor M, Gullestad L, Bjørnerheim R, Simonsen S, Nitter-Hauge S (1998)
[Mortality and morbidity after coronary bypass surgery in high-risk patients]
Tidsskr Nor Laegeforen, 118 (29), 4504-8
PubMed 9889633

Publications 1997

Gullestad L, Myers J, Bjornerheim R, Berg KJ, Djoseland O, Hall C, Lund K, Kjekshus J, Simonsen S (1997)
Gas exchange and neurohumoral response to exercise: influence of the exercise protocol
Med Sci Sports Exerc, 29 (4), 496-502
DOI 10.1097/00005768-199704000-00011, PubMed 9107632

Gullestad L, Nordal KP, Forfang K, Ihlen H, Høstmark A, Berg KJ, Cheng H, Schwartz MS, Geiran O, Simonsen S (1997)
Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin
J Intern Med, 242 (6), 483-90
DOI 10.1111/j.1365-2796.1997.tb00021.x, PubMed 9437409

Gullestad L, Ross H, Myers J, Hoang K, Hunt S, Stinson EB, Valantine HA (1997)
Importance of decreased heart rate in predicting transplant coronary artery disease
Clin Transplant, 11 (6), 628-32
PubMed 9408698

Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB (1997)
AT1 and AT2 angiotensin receptor gene expression in human heart failure
Circulation, 95 (5), 1201-6
PubMed 9054850

Kløw NE, Smith HJ, Gullestad L, Seem E, Endresen K (1997)
Outcome of bypass surgery in patients with chronic ischemic left ventricular dysfunction. Predictive value of MR imaging
Acta Radiol, 38 (1), 76-82
PubMed 9059406

Ross HJ, Gullestad L, Pak J, Slauson S, Valantine HA, Hunt SA (1997)
Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study
J Heart Lung Transplant, 16 (2), 179-89
PubMed 9059929

Aaser E, Gullestad L, Tølløfsrud S, Lundberg J, Hall C, Djøseland O, Kjekshus J, Forfang K (1997)
Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure
Scand J Clin Lab Invest, 57 (4), 361-7
DOI 10.3109/00365519709099409, PubMed 9249883

Publications 1996

Gullestad L, Hallen J, Medbø JI, Grønnerød O, Holme I, Sejersted OM (1996)
The effect of acute vs chronic treatment with beta-adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women
Br J Clin Pharmacol, 41 (1), 57-67
DOI 10.1111/j.1365-2125.1996.tb00159.x, PubMed 8824694

Gullestad L, Haywood G, Ross H, Bjornerheim R, Geiran O, Kjekshus J, Simonsen S, Fowler M (1996)
Exercise capacity of heart transplant recipients: the importance of chronotropic incompetence
J Heart Lung Transplant, 15 (11), 1075-83
PubMed 8956116

Gullestad L, Myers J, Noddeland H, Bjørnerheim R, Djøseland O, Hall C, Gieran O, Kjekshus J, Simonsen S (1996)
Influence of the exercise protocol on hemodynamic, gas exchange, and neurohumoral responses to exercise in heart transplant recipients
J Heart Lung Transplant, 15 (3), 304-13
PubMed 8777215

Haywood GA, Rickenbacher PR, Trindade PT, Gullestad L, Jiang JP, Schroeder JS, Vagelos R, Oyer P, Fowler MB (1996)
Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria
Heart, 75 (5), 455-62
PubMed 8665337

Risum O, Abdelnoor M, Svennevig JL, Levorstad K, Gullestad L, Bjørnerheim R, Simonsen S, Nitter-Hauge S (1996)
Diabetes mellitus and morbidity and mortality risks after coronary artery bypass surgery
Scand J Thorac Cardiovasc Surg, 30 (2), 71-5
DOI 10.3109/14017439609107245, PubMed 8857678

Ross HJ, Gullestad L, Hunt SA, Tovey DA, Puryear JB, McMillan A, Stinson EB, Valantine HA (1996)
Early Doppler echocardiographic dysfunction is associated with an increased mortality after orthotopic cardiac transplantation
Circulation, 94 (9 Suppl), II289-93
PubMed 8901762

Publications 1995

Andreassen AK, Gullestad L, Bjørnerheim R, Forfang K, Kjekshus J (1995)
[Intermittent claudication and beta-blockaders. An unfortunate combination?]
Tidsskr Nor Laegeforen, 115 (6), 725-8
PubMed 7900137

Forfang K, Gullestad L (1995)
[Drug therapy of angina pectoris. Are the possibilities exploited well enough?]
Tidsskr Nor Laegeforen, 115 (18), 2264-7
PubMed 7652725

Gullestad L, Hallén J, Sejersted OM (1995)
K+ balance of the quadriceps muscle during dynamic exercise with and without beta-adrenoceptor blockade
J Appl Physiol (1985), 78 (2), 513-23
DOI 10.1152/jappl.1995.78.2.513, PubMed 7759420

Gullestad L, Osnes JB (1995)
[Beta 3-receptors: incidence and properties, possible clinical significance]
Tidsskr Nor Laegeforen, 115 (1), 45-9
PubMed 7846660

Gullestad L, Simonsen S, Kjekshus J (1995)
[Reduced physical tolerance in patients with heart failure. Mechanisms and therapeutic effects]
Tidsskr Nor Laegeforen, 115 (1), 38-42
PubMed 7846658

Simonsen S, Forfang K, Gullestad L, Geiran O (1995)
[Treatment of terminal heart failure]
Tidsskr Nor Laegeforen, 115 (4), 467-70
PubMed 7871502

Simonsen S, Gullestad L, Forfang K, Ihlen H, Nordal KP, Geiran O, Høstmark AT (1995)
[Hypercholesterolemia--a clinical problem in heart transplantation. A therapeutic trial with low-dose lovastatin]
Tidsskr Nor Laegeforen, 115 (3), 357-9
PubMed 7855835

Publications 1994

Børsheim E, Bahr R, Hansson P, Gullestad L, Hallén J, Sejersted OM (1994)
Effect of beta-adrenoceptor blockade on post-exercise oxygen consumption
Metabolism, 43 (5), 565-71
DOI 10.1016/0026-0495(94)90197-X, PubMed 7909912

Gullestad L, Jacobsen T, Dolva LO (1994)
Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients
Diabetes Care, 17 (5), 460-1
DOI 10.2337/diacare.17.5.460, PubMed 8062622

Gullestad L, Midtvedt K, Dolva LO, Norseth J, Kjekshus J (1994)
The magnesium loading test: reference values in healthy subjects
Scand J Clin Lab Invest, 54 (1), 23-31
DOI 10.3109/00365519409086506, PubMed 8171268

Gullestad L, Nes M, Rønneberg R, Midtvedt K, Falch D, Kjekshus J (1994)
Magnesium status in healthy free-living elderly Norwegians
J Am Coll Nutr, 13 (1), 45-50
PubMed 8157853

Hallén J, Gullestad L, Sejersted OM (1994)
K+ shifts of skeletal muscle during stepwise bicycle exercise with and without beta-adrenoceptor blockade
J Physiol, 477 (Pt 1), 149-59
DOI 10.1113/jphysiol.1994.sp020179, PubMed 8071881

SEJERSTED OM, HALLEN J, GULLESTAD L (1994)
BETA-ADRENERGIC CONTROL OF POTASSIUM SHIFTS DURING EXERCISE
EUROPEAN SECTION MEETING - INTERNATIONAL SOCIETY FOR HEART RESEARCH, 151-158

Publications 1993

Andreassen AK, Gullestad L (1993)
[Alpha blockers--first choice or second choice antihypertensive preparations?]
Tidsskr Nor Laegeforen, 113 (10), 1256-7
PubMed 8098555

Gullestad L, Birkeland K, Mølstad P, Høyer MM, Vanberg P, Kjekshus J (1993)
The effect of magnesium versus verapamil on supraventricular arrhythmias
Clin Cardiol, 16 (5), 429-34
DOI 10.1002/clc.4960160512, PubMed 8504578

Gullestad L, Hallén J, Sejersted OM (1993)
Variable effects of beta-adrenoceptor blockade on muscle blood flow during exercise
Acta Physiol Scand, 149 (3), 257-71
DOI 10.1111/j.1748-1716.1993.tb09621.x, PubMed 7906074

Publications 1992

Gullestad L, Dolva LO, Søyland E, Manger AT, Falch D, Kjekshus J (1992)
Oral magnesium supplementation improves metabolic variables and muscle strength in alcoholics
Alcohol Clin Exp Res, 16 (5), 986-90
DOI 10.1111/j.1530-0277.1992.tb01906.x, PubMed 1443440

Gullestad L, Dolva LO, Waage A, Falch D, Fagerthun H, Kjekshus J (1992)
Magnesium deficiency diagnosed by an intravenous loading test
Scand J Clin Lab Invest, 52 (4), 245-53
DOI 10.3109/00365519209088355, PubMed 1439510

Gullestad L, Forfang K, Simonsen S (1992)
Differential effect of selective beta 1 and nonselective beta-adrenoceptor blockade on epinephrine and atropine response in normal humans
J Cardiovasc Pharmacol, 20 (6), 976-81
DOI 10.1097/00005344-199212000-00019, PubMed 1282602

Gullestad L, Kjekshus J (1992)
[Myocardial disease in diabetes mellitus]
Tidsskr Nor Laegeforen, 112 (8), 1016-9
PubMed 1553723

Gullestad L, Kjekshus J (1992)
[Sudden cardiac death. Significance of beta blockaders]
Tidsskr Nor Laegeforen, 112 (22), 2843-7
PubMed 1357774

Publications 1991

Birkeland KI, Gullestad L, Torsvik H (1991)
[Cholesterol-lowering effect of oat]
Tidsskr Nor Laegeforen, 111 (17), 2081-5
PubMed 1871737

Gullestad L, Birkeland K, Nordby G, Larsen S, Kjekshus J (1991)
Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men
Br J Clin Pharmacol, 32 (2), 201-7
DOI 10.1111/j.1365-2125.1991.tb03882.x, PubMed 1681847

Gullestad L, Fløgstad T, Nordstrand K, Smith G, Smith H, Frøysaker T, Simonsen S (1991)
Intrapericardial left atrial aneurysm diagnosed by transoesophageal echocardiography and nuclear magnetic resonance imaging
Eur Heart J, 12 (2), 277-9
DOI 10.1093/oxfordjournals.eurheartj.a059881, PubMed 2044565

Gullestad L, Oystein Dolva L, Birkeland K, Falch D, Fagertun H, Kjekshus J (1991)
Oral versus intravenous magnesium supplementation in patients with magnesium deficiency
Magnes Trace Elem, 10 (1), 11-6
PubMed 1814318

Publications 1990

BIRKELAND KI, GULLESTAD L, FALCH D, TORSVIK H (1990)
OAT BRAN AND SERUM-CHOLESTEROL
N. Engl. J. Med., 322 (24), 1748-1749

Publications 1989

Gullestad L, Dolva LO, Kjeldsen SE, Eide I, Kjekshus J (1989)
Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise
Cardiovasc Drugs Ther, 3 (1), 63-71
DOI 10.1007/BF01881530, PubMed 2577280

Gullestad L, Dolva LO, Nordby G, Skaaraas K, Larsen S, Kjekshus J (1989)
The importance of potassium and lactate for maximal exercise performance during beta blockade
Scand J Clin Lab Invest, 49 (6), 521-8
DOI 10.3109/00365518909089131, PubMed 2574496

Gullestad L, Dolva LO, Søyland E, Kjekshus J (1989)
[Beta blockaders and physical performance. Limiting factors]
Tidsskr Nor Laegeforen, 109 (25), 2544-7
PubMed 2573167

Gullestad L, Dolva LO, Aase O, Kjekshus J (1989)
Interaction of naloxone and timolol on maximal exercise capacity and the subjective perception of fatigue
Int J Sports Med, 10 (4), 259-63
DOI 10.1055/s-2007-1024912, PubMed 2606592

Publications 1988

Gullestad L, Dolva LO, Søyland E, Kjekshus J (1988)
Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise
Clin Physiol, 8 (5), 487-99
DOI 10.1111/j.1475-097X.1988.tb00214.x, PubMed 3191663

Publications 1987

Gullestad L, Dolva LO, Kjeldsen SE, Eide I, Kjekshus J (1987)
The effects of naloxone and timolol on plasma catecholamine levels during short-term dynamic exercise
Scand J Clin Lab Invest, 47 (8), 847-51
PubMed 2893446

Gullestad L, Søyland E, Dolva LO, Kjekshus J (1987)
[Angiotensin-converting enzyme inhibitors in heart failure]
Tidsskr Nor Laegeforen, 107 (25), 2112-6
PubMed 2823410

Gullestad L, Søyland E, Kjekshus J, Aase O, Bjørnstad P (1987)
[Magnesium deficiency. Diagnosis and occurrence of different disease conditions]
Tidsskr Nor Laegeforen, 107 (22), 1751-4
PubMed 3660356

Publications 1986

Gullestad L, Søyland E, Kjekshus J (1986)
[Magnesium and cardiovascular diseases]
Tidsskr Nor Laegeforen, 106 (7), 554-7
PubMed 3961781

Publications 1979

Gullestad L, Krüger MB, Krüger O, Bakketeig LS (1979)
[Smoking habits among pregnant women in Trøndelag]
Tidsskr Nor Laegeforen, 99 (12), 575-9
PubMed 442031

Page visits: 7131